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Insomnia is a c o m m o n and disabling complaint, which may lead to significant 
clinical and economic consequences. The conventional medications used for treating 
insomnia pose problems including addiction, rebound insomnia upon withdrawal, and 
depression. Thus, there is a need for better therapeutics. Recently, a Chinese herbal 
medicine formula, SD, has been developed based on various Chinese folk recipes for 
a clinical trial in treating sleep disorder. The S D formula consists of six herbs, namely 
Ziziphus jiijuba, Polygonum multiflorum, Poria cocos, Triticum aestivum, 
Anemarrhena asphodeloides, and Poly gala tenuifolia. This formula was employed in 
m y study. 
Increasing evidence shows that fruit fly (Drosophila melcinogester) exhibits a 
sleep-like state which is similar to human sleep. The c o m m o n features of sleep 
behavior between the two species include: i) increased arousal thresholds during sleep, 
ii) the sleep is under homeostatic regulation, and iii) the sleep time can be altered by 
stimulants and hypnotics. 
To investigate the hypnotic effects of the S D formula, I have employed a 
Drosophila insomnia model. The Drosophila sleep model possesses advantages such 
as rapid drug screening and easy to monitor. Caffeine, a commonly used stimulant and 
somnolytic agent, which has been used to induce insomnia in various animal models 
such as rats, was used as a sleep-disrupting agent in the fruit 11 y sleep model to mimic 
the insomnia condition. The fruit flies were fed with caffeine and their daily resting 
durations were recorded. The results indicated the S D formula at the dosage of 50 
mg/ml can attenuate caffeine-induced wakefulness, which further supports the use of 
S D for treatment of insomnia. Short-sleep mutants were also used to study the effect 
of the S D in the model. And real-time P G R was used to study mechanism of S D 
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每日睡眠的時間會被記錄下來。結果顯示安神方劑在 5 0 m g / m l的劑量能改善咖 
啡因誘導的失眠狀况’為使用安神方劑來治療失眠提供進一步的科學實驗依據。 
短睡眠的基因變異果繩亦會用來研究安神方劑的效用。而實時營光定量聚合g每鏈 
反應（Real-time P C R )會用來研究安神方劑與 A P - 1路徑有關的作用機理。 
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1.1 General introduction of sleep 
Sleep is an essential and ubiquitous biological process. It has been identified in all 
species of mammals, birds, reptiles that have been properly investigated and recently also 
identified in the zebra fish and in the invertebrates fruit flies and roundworms (Campbell and 
Tobler, 1984;Shaw et al., 2000;Zimmerman et al.，2008). Though the function of sleep 
remains elusive, it has been proposed that sleep play roles in behavioural adaptation, energy 
conservation (Benington and Heller, 1995), body and brain restoration, learning and memory 
consolidation (Benington and Frank, 2003), hormonal and immunologic processes (Krueger 
and Majde, 2003), and body temperature regulation (Rechtschaffen et al., 1989). 
Sleep is controlled by two major regulatory systems: a circadian system that drives it 
with a 24-hour periodicity to control the timing of sleep and a homeostatic system that 
ensures that adequate amounts of sleep are obtained. 
1.1.1 Sleep disorders 
Sleep disorders are medical disorders of the sleep pattern. There are more than 100 
sleep/wake disorders identified (Mahowald and Schenck, 2005). Most of the sleep 
complaints can be classified into one of four categories: hypersomnia, insomnia, circadian 
rhythm sleep disorder, and parasomnia. Hypersomnia describes the condition of excessive 
1 
Introduction 
daytime sleepiness despite adequate sleep time. Examples are obstructive sleep apnoea and 
narcolepsy. Insomnia describes the difficulty in falling asleep or maintaining sleep. 
Circadian rhythm sleep disorders occur when the biological clock is disturbed or abnormally 
regulated. It reflects the condition of inability to sleep during the desired sleep time. 
Examples are delayed sleep phase syndrome and advanced sleep phase syndrome. 
Parasomnia describes undesired events that intrude into or occur during sleep, but do not 
produce a primary complaint of insomnia or excessive sleepiness, such as nightmares, sleep 
terrors, and sleepwalking (Shneerson, 2005). 
1.1.2 Classification systems for sleep disorders 
There are three major classification systems for sleep disorders used by the 
professionals: The International Classification of Diseases (ICD) by the World Health 
Organization ( W H O ) , Diagnostic and Statistical Manual on Mental Disorders, fourth edition 
(DSM-IV) by the American Psychiatric Association (APA) and The International 
Classification of Sleep Disorders-Revised (ICSD-R) by the American Academy of Sleep 
Medicine ( A A S M ) . These systems categorize the diagnosis of various sleep disorders. In 
general, the ICD has the broadest, least well described categories, D S M - I V has somewhat 
more specific categories, and the ICSD has the most specific of all. The three classification 
systems basically describe three major categories of insomnia: 1) insomnia secondary to 
other conditions, 2) insomnia as a symptom of other specific sleep disorders, and 3) primary 
2 
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insomnia. The categories of the three classification systems are summarized in Table 1.1. 
Table 1.1. Diagnostic classifications for sleep disorders. (Modified from Buysse DJ, 2003) 
I C D - 9 C M D S M - I V ICSD 
• Sleep disorders: • Primary sleep disorders: • Dyssomnias: 
o Disorders of initiating o Dyssomnias o Intrinsic sleep disorders 
and maintaining sleep, o Parasomnias 〇 Extrinsic sleep 
disorders of excessive • Sleep disorders related disorders 
sleep, disorders of the to another mental o Circadian rhythm sleep 
sleep-wake schedule, disorder disorders 
sleep apnea, narcolepsy • Sleep disorders due to • Parasomnias 
• Non-organic sleep medical disorder • Sleep disorders 
disorders: • Substance-induced associated with mental, 
o Insomnia, hypersomnias, sleep disorder neurological, or medical 
disorders of the disorders 
sleep-wake schedule, 
sleepwalking, sleep 





The term insomnia derived from the Latin somniis (sleep), suggesting the stale of not 
being sleep. Nowadays, insomnia is used in a variety of ways in medical literatures as well 
as public press (Roth, 2007). Most commonly, insomnia describes an individual's feeling of 
inadequate sleep. Insomnia can be also used to describe the condition of disturbed sleep. 
Evidence of disturbed sleep includes the presence of a long sleep latency, frequent 
awakenings during the night, or prolonged periods of wakefulness during the sleep period or 
even frequent transient arousals (Sateia et al., 2000). In literature of sleep research, insomnia 
is also used to describe the presence of polysomnographic evidence of disturbed sleep. 
The definition of insomnia should include three criteria. Firstly, insomnia is defined by 
the individual's experience or perception of the inability to obtain sufficient length or quality 
of sleep, not the actual minutes or hours without sleep. This is because every person may 
need different amount of time for sleep to feel refreshed on the next morning. Therefore, 
insomnia should not be defined by the total amount of sleep time of a person. Ironically, the 
total sleep time is one of important parameters for objective measurement of sleep in 
scientific research; sleep researchers must use some criteria to categorize individuals for 
epidemiological studies or clinical therapeutic trials. Secondly, this difficulty is present 
although there is adequate opportunity and lime to sleep. Lastly, the disturbed sleep must be 
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associated with daytime impairment or distress, because when w e consider insomnia as a 
disorder, there must be negative consequence (Roth, 2007). Insomnia should not merely be 
the disturbed pattern or quality of sleep; or otherwise it would not cause problems to daily 
life. Daily associated consequences include change in alertness, energy level, cognitive 
function, behavior or emotional state (Sateia et al., 2000). Sometimes, the duration and 
frequency of the problem is also concerned, though there is no fixed benchmark for duration 
and frequency of symptoms (Attarian et al., 2004). Most clinical researchers require the 
subjects experience problems on at least 3 nights per week and has been a problem for at 
least 1 month (Roth, 2007). Therefore, in summary, insomnia is “a perception of insufficient 
or poor quality sleep, despite adequate opportunity for sleep, leading to a feeling of being 
unrefreshed on waking or during wakefulness, and daily associated consequences “ 
(Shneerson, 2005). The occurrence and duration of the insomnia is also a consideration in 
diagnosis of insomnia. 
Clinically, insomnia is operationally defined by the patient's subjective report of 
difficulty initiating or maintaining sleep, early awakening, and interrupted or non-restorative 
sleep (Sateia and Nowell, 2004). The Sleep Disorders Workgroup of the Diagnostic and 
Statistical Manual Committee of the American Psychiatric Association defines diagnostic 
criteria that require problems of sleep onset, maintenance, early awakening, or 
non-restorative sleep on more than half of the days for at least 1 month that are associated 
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with significant daytime dysfunction that impair performance of activities at home or work 
(Becker, 2006). 
1.2.2 Consequences of insomnia 
Insomnia not only causes nights of restless, sleep dissatisfaction and frustration, 
persistent insomnia may also result in many daily associated consequences including 
sleepiness, depressed mood, anxiety, fatigue, irritability, reduced attention and concentration, 
poor coordination and memory lapses and cognitive impairment, which can affect the 
physical, emotional, cognitive, occupational, and social areas of life (Morin and Gramling, 
1989). Therefore, patients with insomnia often have substantial impairments in quality of 
life. 
Physical effects like fatigue or tiredness are more likely to be reported by people with 
chronic insomnia (Stepanski et al., 1989), but actual daytime sleepiness is less common. In 
fact, many individuals with insomnia are unable to sleep during the day even though they 
feel tired. It has been found out that insomniacs have more days with limited activity, and 
spend more days in bed than people without insomnia. 
Psychiatric disorders, like anxiety and depression, are thought to be both the cause and 
result of persistent insomnia (Benca et al., 1992). However, in a large scale population-based 
study in Europe (Ohayon and Roth, 2003), it was found that insomnia more often preceded 
rather than followed incident cases of mood disorder. Several studies have shown that 
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insomniacs have a higher risk factor for the later development of depression and m o o d 
disorders (Riemann and Voderholzer, 2003;Breslau et al., 1996). These suggested that 
insomnia is one of the major factors that cause psychiatric disorders. 
Problems of depression, irritability, fatigue and decreased concentration diminish 
insomniac's working performance and hence the productivity. It has been shown that 
workers with insomnia always have higher rates of absenteeism (Leger et al., 2006). This 
makes them have less occupational advancement than people without insomnia (Leigh, 
1991). 
Insomnia also increases the occurrence of both traffic and industrial accidents, which 
poses the greatest risk to public health. It has been reported that insomniacs were 2.5 to 4.5 
times more likely to have an accident then people without insomnia (Baiter and Uhlenhuth, 
1992). Sleepiness and reduction in attention and concentration reduce driving performance 
of the driver and cause driving accidents (Aldrich, 1989). It has been also reported that 
insomnia increased the risk of falls in elderly (Koski et al., 1998). One survey in France 
which sampled 8,625 community respondents reported that 8 % of insomniacs and 1 % of 
non-insomniacs had an industrial accident in the past 12 months (Leger et al., 2002). 
Therefore, insomniacs have an increased utilization of the medical care services. As a 
result, consequences of insomnia create a huge economic burden in the society, either 
through direct treatment costs, or indirectly through increased health care costs, 
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ramifications of accidents, reduced productivity due to absenteeism and decreased work 
efficiency (Walsh, 2004). In 1994，it was estimated that insomnia cost the U S public 92.5 to 
107.5 billion dollars (Stoller, 1994). 
1.2.3 Prevalence 
Insomnia is the most c o m m o n sleep disorder and the second most c o m m o n complaint, 
after pain, that causes people to seek medical help (Mahowald et al., 1997). Almost all 
people have been suffering from it at some stage in their lives. Surveys indicated that about 
30 to 50 % of the general population in Western industrialized countries were affected by 
mild or occasional insomnia, and about 9 to 15 % have serious or chronic problems. 
Prevalence of insomnia varies with age and gender. Insomnia occurs more frequently in 
w o m e n and older adults. There was a 1.5 times greater prevalence in females than in males 
(Klink et al., 1992), and almost no complaints of insomnia in the young population of age 
8-10 years old, but serious complaints in 25 to 3 5 % of retirees. Insomnia also occurs more 
often in people with psychiatric disorders, substance abuse and recurrent problems 
(Moorcroft, 2003). 
In Hong Kong, a population study via random telephone survey reported that there was 
about 12% of Hong Kong Chinese suffering from insomnia (Li et al., 2002). Another study 




1.2.4 Subtypes of insomnia 
Insomnia can arise from multiple environmental, medical, psychological, and mental 
disorders (Kupfer and Reynolds, III, 1997). It is a clinical symptom for over 30 sleep 
disturbance diagnostic subtypes and people with insomnia represent a large set of sleep 
disorders (Nau and Lichstein, 2005). Because the term insomnia is so general that it does not 
specify a particular pattern of sleep difficulty or underlying problem, further description is 
necessary to characterize an individual's complaint. This results in development of various 
terminologies to describe the pattern and the duration of the sleep disturbances. Insomnia 
can be separated into subtypes with different patterns, durations, and causes. 
Patterns of insomnia 
Insomnia can be separated into three patterns: sleep onset insomnia, sleep maintenance 
insomnia and early arousal insomnia. 
Sleep onset insomnia refers to the conditions that the patient has difficulty falling asleep. 
People with this type of insomnia need a long time to fall asleep. According to occurrence of 
complaint in population studies, a sleep latency threshold of 30 minutes has been decided to 
distinguish patient with sleep onset insomnia from those without the disease (Lichstein et al., 
2004). People who take longer than 30 minutes to fall asleep can be diagnosed to have sleep 
onset insomnia. This type of insomnia often due to a high level of arousal associated with 
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anxiety, and other factors. 
Sleep maintenance insomnia refers to the conditions that the patient wakes up 
irregularly during nighttime. A person can be diagnosed to have sleep maintenance insomnia 
if he/she is awake for more than a total of 30 minutes during sleep periods and/or has five or 
more awakenings. 
Early arousal insomnia is a condition that is c o m m o n in elderly. People having this type 
of insomnia often wake up in the early morning without further sleep. A total sleep time of 
less than 6.5 hour has been used as a reference value in diagnosis of this type of insomnia. 
The classification of insomnia based on pattern is of limited value for diagnosis because the 
specific type of sleep complaint often varies within an individual over time (Hohagen et al., 
1994) and a majority of patients actually have more than one type of the sleep disturbances 
at the same time. 
Durations of insomnia 
Insomnia can be divided into acute and chronic (or persistent) insomnia according to 
the duration of the symptoms. In general, an arbitrary cut-off of 4 weeks is used to 
distinguish between acute insomnia and chronic insomnia (American Psychiatric Association, 
1994). 
Acute insomnia refers to insomnia episodes that last for less than 4 weeks. It can occur 
transiently, which is known as transient insomnia, or last persistently for a few weeks, which 
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is known as short-term insomnia. The National Institutes of Health describes transient 
insomnia as insomnia that comes and goes sporadically. Transient insomnia presents for less 
than a week and then passes after a few days. The duration usually lasts for less than 3 weeks 
in which the patient can have some periods of time with no sleep problem, and thus patients 
with transient insomnia seldom seek for treatment. In contrast, short-term insomnia can 
persist for 1-2 weeks. Acute insomnia is often related to specific psychosocial or 
environmental stresses, it can be triggered by factors like changes in sleep environment, 
increased arousal states by emotional events, poor sleep hygiene (e.g. adoption of irregular 
sleep-wake cycle, drinking excess coffee or alcohol), or short-term circadian rhythm 
disorders induced particularly by jet lag and rotating shift work (Shneerson, 2005). Acute 
insomnia generally resolves and is usually not associated with severe complications (Lavie 
et al., 2002). 
Chronic insomnia refers to insomnia that persists unabated for more than 4 weeks. 
Chronic insomnia is more complex than acute transient insomnia. It is more often related to 
intrinsic sleep disorders or primary insomnia. Furthermore, chronic insomnia, unlike acute 
insomnia which resolves after a period of time, often associates with substantial 
consequences, e.g. anxiety and depression. 
Primary and Secondary insomnia 
Insomnia can be classified as primary or secondary insomnia. Primary insomnia has no 
11 
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identifiable cause, while secondary insomnia is caused by another disorder. Secondary 
insomnia is more c o m m o n than primary insomnia (Ohayon, 1997). Primary insomnia is 
sometimes referred to as pure insomnia, to emphasize that difficulty of falling asleep is at the 
core of the disorder. 
1.2.5 Causes 
There are various causes of insomnia. They can be grouped into five general types of 
etiologic factors: circadian factors, psychiatric factors, pharmacologic factors, 
medical/neurological illness and psychophysiologic/conditioning factors (Buysse, 2003). 
These factors m a y act alone or in combination to cause insomnia. M a n y of these primary 
causes can lead to secondary psychophysiologic/conditioning factors as a c o m m o n pathway 
to increase arousal which reinforces insomnia. Psychophysiologic/conditioning factors have 
been portrayed as the most important component of chronic insomnia, since they often 
perpetuate insomnia (Buysse and Reynolds, 1990). Different causes of insomnia are 
summarized in Figure 1.1. Advancing age is considered to be a risk factor for developing 




• Jet lag 
• Shift work 
• Sleep scheduling 
• DSPS and ASPS 
Psychiatric factors 
• Depression Psychophysiologic and 
• Mania conditioning factors 
• Schizophrenia • Psychological factors \ 
• Physiological tension ^ 
• Cognitive overarousal ^ arousal \ 
• Negative sleep habits and 
Pharmacologic factors environment Z r " " ^ 
• Stimulants and alcohols \ 
• Acute effects of drugs ^ ^ V 
• Tolerance and withdrawal ^ ^ ^ 
( insomnia ) 
Medical and neurological illness ^ ^ 
參 Asthma and angina , 
• Hypothalamic and thalamic lesions 
• Parkinsonism and dementia 
• Movement disorders, e.g. RLS, 
PLMS 
Figure 1.1 Causes of insomnia. ASPS: advanced sleep phase syndrome, DSPS: delayed 
sleep phase syndrome, RLS: restless legs syndrome, P L M S : periodic limb movements in 
sleep. (Modified from Buysse, 2003 and Shneerson, 2005) 
1.2.6 Treatment of insomnia 
As insomnia is often caused by multiple factors and is a consequence and combination 
of disturbances in habits, psychological conditions and disturbed circadian rhythm. Specific 
treatment of insomnia may be needed for each of the different conditions. For secondary 
insomnia that, for example, is caused by medical or psychological conditions, such as 
depression, anxiety, pain and use of medicines, the treatment will focus on those conditions. 
For insomnias that are caused by circadian rhythm sleep disorders, chronotherapy (such as 
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light therapy) m a y be useful. For primary insomnia in which poor sleep quality itself is the 
major problem, non-pharmacologic therapy that helps to improve sleep hygiene and sleep 
environment should be taken first. If the problem exists continuously, then hypnotic drugs 
are often used in short term to relieve symptoms. In general, treatments for insomnia can be 
separated into two categories: cognitive-behavioral therapy (CBT) and pharmacological 
treatment. 
1.2.6.1 Cognitive-behavioral therapy for insomnia 
Cognitive-behavioral therapy (CBT) for insomnia is a non-medical approach to 
treatment of insomnia. It focuses on the maintaining factors and uses an evidence based 
approach to treat insomnia. The treatment is conducted and guided by the assessment of the 
insomnia complaint of the patient by the therapist by methods such as clinical review, 
questionnaires, sleep diaries, and actigraphy. C o m m o n forms of C B T for insomnia include 
stimulus control therapy, sleep restriction therapy, relaxation techniques, cognitive 
interventions, and sleep hygiene education. 
Stimulus control therapy 
Stimulus control therapy aims to reinforce associations between sleepiness, sleep and 
the sleep environment. It is the most well-validated therapy of all the available psychological 
treatments and is considered the gold standard for behavioral treatment of insomnia. It is 
14 
Introduction 
recommended for both sleep initiation and sleep maintenance problems. Instructions are 
given to patient to learn to associate the bed and bedroom with sleep. The patients are 
instructed to use the bed and bedroom only for sleep and sexual activity, to limit the amount 
of time staying awake in the bed, and to go to bed only when feeling sleepy. They are told to 
leave the bedroom when awake in bed for more than 20 minutes and return only when feel 
sleepy again. 
Sleep restriction therapy 
Sleep restriction therapy requires the patients to limit the time spent in bed by 
establishing fixed bedtime and rising schedules that closely match their reported actual hours 
of sleep. The aim is to increase sleep efficiency, or the ratio of total time spent asleep to total 
time spent in bed. Sleep restriction therapy is also recommended for both sleep initiation and 
sleep maintenance problems. At the beginning, the reduced amount of sleep time would 
result in slight to moderate sleep deprivation, which increases the daytime fatigue. The 
increase in sleepiness would usually after a few days enhance the ability to fall asleep and to 
maintain sleep. Since sleep restriction can lead to increased daytime sleepiness, patients 
should be cautioned about operating machinery or performing duties that requires high levels 
of alertness. 
Relaxation techniques 
Relaxation techniques aim to relieve muscular tension and reduce cognitive arousal, 
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which are incompatible with sleep. This helps to prepare the patient for sleep and alleviate 
the anxiety. Several specific relaxation techniques such as muscle relaxation, diaphragmatic 
breathing, biofeedback, autogenic training and acupuncture have been used for treating 
insomnia. 
Cognitive interventions 
Cognitive interventions involve the identification, challenge, and change of the negative 
thoughts and beliefs about the patient's conditions and the consequences or fears regarding 
loss of sleep. Those negative thoughts or cognitive distortions are thought to increase arousal 
and tension, which further prevent sleep. Cognitive interventions challenge the catastrophic 
thinking and fears of the patient through education and discussion within a 
psychotherapeutic context to decrease anxiety, arousal and sleep related worry. It is most 
often combined with other behavioral interventions. Different forms of cognitive 
interventions for insomnia include didactic focus, paradoxical intention and distraction and 
imagery. The rationale of the technique paradoxical intention is that actively trying to 
maintain wakefulness will reduce performance anxiety related to falling asleep and thus will 
facilitate sleep onset. Data indicate that paradoxical intentions may provide some benefit, but 
responses are highly variable. 
Sleep hygiene education 
Sleep hygiene education helps patients to be more aware of how the lifestyle can 
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contribute to insomnia so that to enhance the sleep quality. Instructions and advices are given 
to the patients to help them reinforce sleep-promoting behaviors and reduce the frequency of 
behaviors that m a y interfere with sleep. Examples of the advices include doing more 
exercise, keeping a fixed sleep-wake schedule, relaxing evening routines, avoiding 
stimulants and daytime sleep, and reducing alcohol intake. Sleep hygiene education is often 
used together with other behavioral interventions in treating insomnia. 
1.2.6.2 Pharmacological treatment for insomnia 
Pharmacological treatment is the most c o m m o n treatment for insomnia because of 
C B T s need time to learn and time to show its effects, and patients usually need immediate 
aids or are unable to take the time to learn and practice C B T s (Erman, 2005). 
Pharmacological treatment for insomnia generally involves the use of hypnotics to improve 
the quality and duration of sleep, increase the degree of daytime alertness and relieve 
hyperarousal state at night. In the old days, agents like chloral hydrate and barbiturates, 
which can induce drowsiness, have been used for treating insomnia. However, they are no 
longer to be used nowadays because of their high risk of dependency and overdose. 
Currently only benzodiazepine receptor agonists (including benzodiazepines and three 
nonbenzodiazepine hypnotics), and a novel melatonin receptor agonist (ramelteon) have 
been approved for the treatment of insomnia by Food and Drug Administration (FDA). 
However, physicians frequently use drugs from other classes, like antidepressants, to treat 
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insomnia (Erman, 2005). Several most commonly used types of drugs for treating insomnia 
are discussed below. 
Benzodiazepines 
Benzodiazepines were once the most commonly prescribed sedative hypnotics 
(Thompson et al., 1983). The benzodiazepines that approved by the F D A for the treatment of 
insomnia are estazolam, fliirazepam, quazepam, temazepam, and triazolam. They potentiate 
the actions of the neurotransmitter y-aminobutyric acid ( G A B A ) agonist by binding to a 
recognition site, the benzodiazepine receptor, at the interface of the a and y subunits of the 
G A B A A receptor, locking the receptor into a conformation that with a much higher affinity 
for G A B A . This leads to a higher frequency the opening of the associated chloride ion 
channel that mediates inhibitory effects in the C N S and therefore induces sedatory and 
anxiolytic effects. Benzodiazepines are effective and most useful for short-term treatment 
(less than 2 weeks), which have immediate effects after intake. Benzodiazepines have high 
risk of next-day impairments due to their long half-lives. They can cause morning sedation, 
cognitive impairments and motor in-coordination. Long-term usage may also lead to 
problems of abuse and tolerance, and memory impairment. 
Nonbenzodiazepine hypnotics 
Nonbenzodiazepine hypnotics, including zaleplon, Zolpidem and zoplicoline, belong to 
a newer class of benzodiazepine receptor agonists. The three agents are also known as 
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Z-drugs. They have similar effect to benzodiazepines of potentiating the actions of G A B A al 
the benzodiazepine receptor and have comparable hypnotic effect to benzodiazepines, but 
have a structure unrelated to benzodiazepine. Although the exact mechanism of action is 
unknown, it is believed that nonbenzodiazepine hypnotics can bind selectively to one 
particular subtype of benzodiazepine receptors that contains the ai subunit (Griebel et al, 
1999), in contrast to that benzodiazepines can bind all the subtypes. They also have shorter 
half-lives and shorter duration of action than most of benzodiazepines. This results in greater 
effects on sleep onset than sleep maintenance and fewer adverse effects. They have minimal 
morning sedation and lower abuse potentials. However, they can still cause problems like 
headache, amnesia, nausea and rebound insomnia after withdrawal. 
Antihistamines 
Antihistamines can be found in many over-the-counter sleeping medications. 
Diphenhydramine and doxylamine are c o m m o n antihistamines used in sleep medications as 
mild sleep-inducers. Antihistamines are reversible antagonists of C N S histamine Hi 
receptors. They antagonize the action of histamine in the tuberomammillary nuclei of the 
brain which promotes wakefulness, as a result to produce more rapid sleep onset. 
Antihistamines can cause significant side effects like morning sedation, cognitive 





Antidepressants were initially not designed for treating insomnia. However, sedating 
antidepressants likes trazodone and some tricyclic antidepressants (TCAs) are often 
prescribed by physicians for that purpose. A reason for that is that insomnia m a y be caused 
by depression or is often associated with depression symptoms. In addition, some 
antidepressants have sedating properties therefore can be used for treating primary insomnia 
(Erman, 2005). Furthermore, trazodone and T C A s are inexpensive and are not controlled 
substances, which do not require special prescriptions and have no refill limitations (Erman, 
2005). Trazodone is an example of sedating antidepressants that has been frequently 
prescribed in low doses as a hypnotic to help induce sleep. The mechanism of action of 
trazodone is not fully understood. It is thought to be related to the serotonergic pathway, 
possibly through antagonistic effects at 5-HT2a receptor, though it possesses mixed 
pharmacological properties, including moderate antihistaminergic activity and weak oti 
antagonistic activity which could contribute to the sedative properties (Owens et al., 1997). 
T C A s that have been used for treating insomnia include doxepin, trimipramine, and 
amitriptyline. They inhibit both serotonin and norepinephrine reuptake transporters and also 
may antagonize actions of histamine. Trazodone and T C A s can have significant side effects 
such as orthostatic hypotension, blurred vision, dry mouth, constipation, drowsiness, and 
headache. There are few studies on the safety and efficacy for using sedating antidepressants 
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for treating insomnia in non-depressed patients. 
Melatonin receptor agonists 
Melatonin is a hormone that participates in the regulation of circadian rhythm. It is 
produced by the pineal gland and secreted exclusively at night. The production of melatonin 
is suppressed by bright light and regulated by the biological clock. The mechanism of 
actions of melatonin in regulating sleep-wake cycle is through its interaction with specific 
receptors (MTi and M T 2 ) in the suprachiasmatic nucleus (SCN) of the anterior 
hypothalamus, where is the site of the circadian pacemaker. M T i is thought to regulate 
sleepiness, while M T 2 is more likely to be involved in the readjustment of the circadian 
rhythm. Therefore, melatonin can affect sleep as both a chronobiotic that shifts the circadian 
rhythms and a hypnotic that induce sleep. A novel melatonin receptor agonist known as 
remelteon was approved by the F D A in 2005 for treatment of insomnia. It is the first 
approved drug for treating insomnia that with a different mechanism of action from 
benzodiazepine receptor agonists in that it stimulates the melatonin receptors in the brain. 
Melatonin receptor agonist may be also useful in the treatment of insomnia caused by jetlag 
and shift work to adjust right the biological clock. There are relatively few side effects 
reported for ramelteon, suggesting that it is a promising alternative to sedative-hypnotics, 




1.3 Traditional Chinese medicine and herbs in SD formula 
Apart from the treatment of insomnia using western drug, traditional Chinese medicine 
( T C M ) also has a long history in treating insomnia among Chinese populations. It was 
renowned for its low cost and milder side effects. While T C M holds a different point of view 
in the theory of causes and underlying principle of insomnia, which views insomnia as a 
result of underlying disturbance in the balance between Yin and Yang and the interaction of 
five basic elements and the vital organs (Wing, 2001), the effectiveness of the outcome 
treatment of this holistic view on treating diseases in T C M is worth studying. T C M herbs are 
rarely used alone but rather in combination formulas. The herbs in the S D formula come 
from ancient folk formula suggested they have potential therapeutic effects in treating 
insomnia. They are introduced one by one below. 
Ziziphus jujuba (Suanzaoren S曼棗仁） 
Suanzaoren is dried ripe seed of the Ziziphus jujuba. In theory of T C M , it nourishes the 
liver and quiets the heart to treat liver/heart imbalance, which can calm the spirit and 
contract sweating and relieving mental stress. Animal studies suggest that it may protect 
cerebral ischemic injuries, has hypnotic effects in rats ( W u et al., 1993), modulates 
stress-induced sleep changes in mice (Saito et al., 2000), and enhances total sleep time and 
slow wave sleep in rabbits (Shiyi, 2000). 
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Polygonum multiflorum (Yejiaoteng 夜交藤) 
Yejiaoteng, which also named as Shouwuteng, is the dried stem of Polygonum 
multiflorum. It can also nourish the heart and tranquilize the mind in the theory of T C M . It is 
used for the treatment of insomnia and rheumatic diseases. Animal studies with rats suggest 
it increases slow wave sleep, reduces R E M sleep and has a synergistic hypnotic effect with 
pentobarbital (Yang et al., 1990). 
Poria cocos (Fushen 获才申） 
Fushen is a dried sclerotium of Poria cocos. In theory of T C M , it quiets the heart and 
spirit. It is used for the treatment of edema, dizziness and palpitations, diarrhea, restlessness, 
and insomnia. 
Triticum aestivum (Fuxiaomai >、字'j、麥) 
Fuxiaomai is the light grain of Triticum aestivum. In theory of T C M , it can nourish the 
heart and tranquilize the mind. It is used for hectic fever and sweating. It is one of the 
component herbs of the traditional formula 'Liquorice, wheat and jujuba soup，which is used 
for treating insomnia. 
Anemarrhena asphodeloides (Zhimu 头口母) 
Zhimu is the dried rhizome of Anemarrhena asphodeloides. In T C M theory, it enriches 
yin and downbears fire, and moistens dryness. It is traditionally used to remove heat and 
quench fire and to promote production of body field and reduce dryness syndrome. 
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Poly gala tenuifolia (Yuanzhi 遠志、) 
Yuanzhi is the dried root of Polygala tenuifolia. In theory of T C M it quiets the spirit, 
sharpens the wits and resolves depression. It has been used to treat insomnia, 
dream-disturbed sleep, forgetfulness and palpation. 
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1.4 Drosophila model for studying sleep 
Animal models are very useful tools for the validation of drug candidates in the process 
of drug development and understanding the functions and molecular mechanisms of 
evolutionary conserved biological processes. A successful simple animal model in sleep, 
which can truly reflect the phenomenon of sleep in human, would sure help identify and 
understand the conserved regulatory mechanisms and uncover functions of sleep. 
Furthermore, the model m a y be able to facilitate the processes of drug screening to discover 
new types of hypnotic and validate their efficacy which m a y help patients suffering from 
chronic insomnia. Following the discovery of the sleep in Drosophila, it became one of such 
useful model for the study of sleep and possibly insomnia. 
1.4.1 Drosophila as a disease model 
Drosophila has been used extensively in many areas of biological research including 
genetics and development. The completed Drosophila genome reveals genes between flies 
and humans are highly conserved. They have a complex nervous system and displays 
complex behaviors such as learning and memory. Drosophila shares a significant number of 
genes important for neural development and function with mammals, including most of the 
major neurotransmitter systems involved in sleep and genes that underlie human 
neurological disease. In the past few decades, the Drosophila model has successfully 
facilitated the understanding molecular basis of neural processes such as circadian rhythm, 
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and learning and memory. 
With the advance in molecular biology, the utility of simple animal model can facilitate 
the progress of research and understandings to more complex state. Small organisms allow 
the technique of molecular biology to apply more efficiently and profitably to address both 
mechanism and function of complex biological phenomenon and disease. 
1.4.2 Drosophila Sleep 
Drosophila sleep was first reported in 2000 (Ho and Sehgal, 2005). The sleep state in 
Drosophila was originally identified on the basis of behavioral criteria (Hendricks et al., 
2000a;Shaw et al., 2000) that used to identify sleep in other organisms (Hendricks et al., 
2000b). These criteria included 1) a species-specific posture and/or preferred resting site, 2) 
consolidated behavioral quiescence regulated in a circadian fashion, 3) an elevated arousal 
threshold that is reversible by intense stimulation, and 4) a homeostatic regulatory 
mechanism that compensates sleep loss after sleep deprivation (Campbell and Tobler, 1984). 
Observation of individual animals revealed that Drosophila rest behavior consisted of 
relaxed immobility in a preferred posture in a more supported position (Hendricks et al., 
2000a). 
1.4.3 Similarity of Drosophila and mammalian sleep 
Sleep in Drosophila melanogaster shares many key characteristics with mammalian 




The reversible state of quiescence is one of the basic requirements for behaviorally 
defining sleep. Flies as mammals exhibit long periods of consolidated immobility both in 
isolated and in social conditions, with the period of immobility can last up to 2.5 hours 
(Hendricks et al., 2000a). The period of immobility is under circadian regulation. The most 
consolidated period of immobility occurs during the dark period of the day. 
Arousal threshold 
As the sleep state in mammals, the quiescent state in tlies is associated with increased 
arousal threshold. Sleeping flies show decreased responsiveness to the external stimulus. A 
study showed that they required increasingly more intense stimulation by tapping on the 
Petri dish in which they were housed in order to keep them active (Hendricks et al., 2000a). 
In another study, active flies were shown to respond to low levels of vibratory stimulation 
with 0.05 and 0.1 g (acceleration), while sleeping flies only respond to the stimulation when 
it was increased to 6 g (Shaw et al, 2000). 
Homeostatic control 
Homeostatic regulation is a key feature of mammalian sleep, in which a sleep deficit 
elevates sleep propensity and increases the deepness and duration of the recovery sleep 
period. Flies were shown to have a sleep time increased 3- to 7-fold after 12 hour of sleep 
deprivation comparing with control flies. In contrast, flies stimulated for 12 hours during 
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normal waking period showed no increase in sleep during subsequent recovery period, 
meaning that the increased sleep is not due to physical exhaustion or to stress from the 
handling method (Shaw et al., 2000). The presence of this sleep rebound suggests sleep in fly 
is under homeostatic regulation as that in mammals. 
Pharmacological studies 
Drosophila has similar responses to mammals on pharmacological treatments that affect 
the sleep. The adenosine receptor antagonist caffeine can increase wakefulness both in flies 
and mammals in a dose-dependent manner (Hendricks et al, 2000a;Shaw et al., 
2000;Fredholm et al., 1999). O n the other hand, a specific agonist of the mammalian 
adenosine receptor Al cyclohexyladenosine ( C H A ) (Strecker et al., 2000), which can 
increase N R E M sleep and decrease waking in mammals, was found to increase sleep in flies 
(Hendricks et al., 2000a). This indicated that the adenosinergic pathway of sleep regulation 
in mammalian species is conserved in flies. Furthermore, the stimulant modafinil have been 
shown to decrease the sleep time in Drosophila (Hendricks et al., 2003), while the 
antihistamine hydroxyzine has been shown to increase the sleep time and decrease sleep 
latency (Shaw et al., 2000). These suggest that the sleep and wake-promoting systems in 
flies are at least pharmacologically similar to those in mammals, implying that Drosophila is 




Sleep in fly is associated with changes in brain electrical activity. Several experiments 
have demonstrated that spike-like potentials in the medial Drosophila brain correlated with 
sleep/wake state (Nitz et al., 2002;van Swinderen and Greenspan, 2003;van Swinderen et al., 
2004). The study measuring both the motor activity levels and the local field potentials 
(LFPs) in the 20-30 H z range in the brain of fruit fly determined that the sleep state in 
Drosophila is accompanied by lowered brain activity (van Swinderen and Greenspan, 2003). 
Fragmented with aging 
In mammals, sleep is abundant in young and is less consolidated in older individuals. 
Similar phenomenon was observed in flies. Newly enclosed flies have more sleep, and their 
total sleep time decrease to reach the adult value of sleep time at the third day after eclosion 
(Shaw et al., 2000). Furthermore, it was found that younger flies have more consolidated 
sleep, and the sleep became fragmented as the flies aged (Koh et al., 2006). 
1.4.4 Methods for measuring Drosophila sleep 
Sleep in mammalian species is measured both behaviorally and electrophysiologically, 
but since sophisticated electrophysiological measurement method in Drosophila have not yet 
been developed, current studies in Drosophila sleep largely relied on the data from activity 
measurements. 
Sleep measurements in fly need apparatus that track the rest and activity behaviors of 
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individual flies over the course of at least a few days. Automated activity monitoring systems 
using ultrasound, infrared light, and videography have been used in combination of visual 
observations to identify sleep-like state in Drosophila, The different monitoring systems 
have varied levels of resolutions on the behavior recording. High-resolution ultrasound 
activity monitoring system can detect the fine movements of head, wings, and limbs of the 
fruit flies (Shaw et al., 2000), which can obtain more detailed information about the 
movement of the fly during sleep, while videography can record the posture and place of 
preference for rest (Hendricks et al., 2000a) and other movement such as grooming (Ho and 
Sehgal, 2005). 
Another automated activity monitoring system is the Drosophila Activity Monitoring 
System (Trikinetics) (Figure 1.2). This system provides robust activity information in a 
circadian organization. It has been widely used in studying sleep in Drosophila. In this 
system, individual fly is housed in an activity tube with food. The tube is then placed in the 
monitor that holds 32 tubes with an infrared beam bisecting the activity tube. The infrared 
sensor can detect the movement of the fly when it deflects the infrared bean when walking 
back and forth in the tube. Number of counts of the crossing the middle of the tube was 
recorded in the computer for analysis. The system has been validated for measuring sleep by 
visual observation (Shaw et al., 2000). The sleep data recorded from this activity monitor 
have shown good correspondence to the high resolution measurement methods and visual 
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observation (Shaw et al., 2000). 
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Figure 1.2 Schematic diagram of the Drosophila Activity Monitoring System. 
1.4.4.1 Surrogate measurement of sleep in Drosophila 
Although the activity counts are inversely related to the occurrence of sleep, activity 
data cannot be directly used to represent sleep because of sleep is not simply just a state of 
immobility. For example, brief pauses in activity should not be treated as sleep. Since sleep 
measurement largely relies on the activity measurement, it is essential to have some method 
for converting the activity counts to the sleep data. Experiments to define a surrogate 
measurement for sleep had been performed by studying the correlation between the duration 
of the immobility together with another essential feature of sleep - the "increased arousal 
threshold" (Shaw et al., 2000). The duration of immobility was correlated to the response of 
the flies to vibratory stimuli. And it has been found that flies that had been behaviorally 
quiescent for 5 minutes or longer rarely showed a behavioral response to these stimuli. 
Periods with greater than 5 minutes of immobility are also regulated homeostatically. The 
consistent association of the increased arousal threshold of Hies with behavioral immobility 
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of greater than 5 minutes during both light and dark periods suggested that behavioral 
immobility lasting 5 minutes or more can be used to define sleep in fly (Shaw et al., 
2000;Huber et al., 2004). 
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1.5 Objectives of study 
Insomnia is a c o m m o n and disabling disorder, which can lead to severe daytime 
consequences that impair the quality of life and create huge economic burden to the society. 
People with insomnia tend to seek pharmacological treatment for immediate relief of the 
insomnia complaint, especially in the case of acute insomnia. However, while 
pharmacological treatments m a y be useful for treating insomnia, most of the drugs that are 
currently available for treating insomnia are effective only for short-term usage. Continuous 
usage of hypnotics will very likely cause tolerance, dependence and addiction to the product. 
Effective agents for insomnia with less adverse effects for long-term use are therefore 
desired. 
Traditional Chinese medicine ( T C M ) has a long history in treating insomnia. 
Experiences suggest that they are potentially effective and safe in use, as no severe side 
effects have been reported from the long term usage of T C M in treating insomnia. However, 
scientific proofs on the efficacy and pharmacologic basis of using T C M to treat insomnia are 
insufficient nowadays. Therefore, it is of interest to study the efficacy and the underlying 
working mechanism of traditional herbal medicine in treating insomnia. 
The purpose of this study was to evaluate the hypnotic effect of the S D formula on a 
Drosophila sleep model. In order to study the effect of SD, a Drosophila insomnia model 
using caffeine to mimic the insomnia condition has to be established and validated. The 
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hypnotic effect of the S D formula was then investigated in the model. The hypnotic effect of 
the S D was also investigated in several short-sleep mutants (fumin, minisleep, and Hk ), 
which have been reported to have less sleep than the wide-type control. To partially reveal 
the working mechanism of S D , the expression levels of several AP-1 related genes {Cyp6a8, 
Djun, Dfos) were also tested, which m a y shed light on the regulatory mechanism of sleep 
related to the AP-1 pathway. 
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2. Materials and Methods 
2.1 Preparation of the Sleep Disorder (SD) extract 
The Sleep Disorder (SD) formula consists of six herbs, namely Ziziphus jujuba 
(Suanzaoren), Polygonum multiflorum (Yejiaoteng), Poria cocos (Fushen), Triticum aestivum 
(Xiaomai), Anemarrhena asphodeloides (Zhimu), and Poly gala tenuifolia (Yuanzhi). It is a 
modified version of the combination of two Chinese folk formula: i) Spiny Jujube Decoction 
(酸棗仁湯）from Jin Gui Yao Lue (金 1 要略）and ii) Orientation-Stabilizing Pill (定志丸） 
from Qian Jin Fang (千金方）.The herbs Ziziphus jujuba, Poria cocos, Anemarrhena 
asphodeloides come from the Spiny Jujube Decoction, which is traditionally used to nourish 
the blood and calm the spirit, clear heat and eliminates vexation. It has been used to treat 
vacuity vexation, insomnia or ungratifying sleep, excitability and irascibility, headache and 
feeling of distention in the head. The herbs Polygala temiifolia and Poria cocos come from 
Orientation-Stabilizing Pill, which is traditionally used to boost qi and nourish the heart, and 
quiet the spirit. It has been used to treat fright palpitations and poor memory. M a n y of the 
above-mentioned herbs are used for tranquilizing the mind, which is somewhat as analgesic 
effect. The use of a combination of herbs is to obtain a synergistic effect on treating insomnia. 
The voucher specimen numbers and places of origin of the six component herbs were given 
in Table 2.1. 
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Table 2.1. Origins and voucher specimen numbers of the six component herbs in the SD formula. 
Herbs Places of origin Voucher specimen numbers 
Ziziphus jujuha Yunnan 2006-2963 
Polygonum multiflorum Guangdong 2006-2967 
Poria cocos Anhui 2006-2960 
Triticum aestiviim Hebei 2006-2962 
Anemarrhena . , . 。八^广。八<< 
Anhui 2006-2965 
asphodeloides 
Polygala temiifolia Shandong 2006-2964 
The extract of the S D formula was manufactured by the following protocol. The herbs 
were cut into pieces with length, width and thickness of less than 6 cm. The processed herbs 
were boiled in ten folds of water (by weight) for 1 hour and then boiled twice in eight folds 
of water for 1 hour. The extract from the three extractions was combined together and 
concentrated under reduced pressure to form paste, which was then dried by heat and was 
packed into plastic bottles at approximately 100 g each. The extraction yield of the 
manufacturing was 7.96%. 
The extract from the plastic bottles was powdered and dissolved in ten folds of water by 
weight and then subjected to ethanol precipitation to remove impurities (Chen et al., 2000). 
Five times the volume of water of ethanol was added and the mixture was allowed to stand at 
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40C for overnight. The mixture was then centrifuged at 3000 x ^  at 4°C for 10 minutes for 
removal of residue and the supernatant was concentrated under reduced pressure at 56()C on a 
rotary evaporator and then lyophilized on freeze dryer. The dried extract was stored in 
desiccator at room temperature. The yield of ethanol precipitation was 52%. 
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2.2 Establishment of the Drosophila sleep model 
2.2.1 Drosophila culture 
2.2.1.1 Fly stock 
The standard wide-type strain Canton-S (CSl) obtained from Professor Edwin Chan, 
Laboratory oi Drosophila Research, C U H K , was employed in the Drosophila sleep model. 
2.2.1.2 Fly food 
The medium used for growing flies contained cornmeal, dextrose and yeast. For 
preparation of 500 ml of fly food, 3 g agar, 40 g of cornmeal, 40 g of dextrose, and 8.3 g dry 
yeast were mixed in 500 ml of water. The mixture was boiled for 8-10 minutes in a 
microwave oven. After the mixture was cooled to around 5 ml 10% methyl 
4-hydroxybenzoate (Sigma) in elhanol was added to inhibit fungal growth. Then 15 ml of the 
fly food was dispensed per vial and was allowed for cool. 
2.2.1.3 Culture environment 
Flies were raised in plastic vials containing 15 ml of the fly food. The vials containing 
the flies were kept in a well-humidified incubator (LMS) with constant temperature at 25。C 
and a 12 hour: 12 hour light: dark cycle to mimic the natural conditions. A lamp was installed 
in the incubator and the lighting condition was controlled by a digital timer. Water was added 
to the vials to moisturize the food when the food was appeared to be dry. 
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2.2.2 Preparation of flies for experiments 
The wide-type Canton-S fly line was used in the sleep model. Flies of age 5-7 days were 
used as previously mentioned (Ruber et al., 2004;Shaw et al, 2000) and were prepared as 
following described. The parental generation was allowed to mate and lay eggs on new vials 
with food for 5 days, after that they were removed. Newly eclosed flies were collected and 
they were transferred into new vials every 2 days after emergence at about day 10 (Figure 
2.1). The collected flies were used after 5 days when they were 5-7-day-old. 
Collect flies for use 
Remove parental flies Day 12 Day 14 Day 16 
mmmsmmmmmmmmmmmmimmK^ : mmmsm ^ mmmmm ^ mmm^ ^ mmmmm^mm^^ 
K ^ y J “ • � — ] 
V ‘ •! Day 17 | 
Day 0-5 Day 10 i Flies collected on 
Mate and lay eggs Start emerging I day 12 reach the age 
I 5-7 days old 
Figure 2.1. Schematic diagram of preparation of flies for experiments. 
2.2.3 Agar food and drug preparation 
The food used in the sleep model was made up of 1 % agar and 5 % sucrose. For 
preparation of 50 ml 1 % agar and 5 % sucrose solution, 0.5 g agar and 2.5 g sucrose was 
mixed in 50 ml of water and the solution was then boiled in microwave oven for about 2 
minutes. The food containing 25 mg/ml, 50 mg/ml, 100 mg/ml S D extract was prepared by 
dissolving 0.375 g, 0.75 g, 1.5 g of the S D extract, respectively, in 15 ml of 1 % agar and 5 % 
sucrose solution when the agar-sucrose solution was cooled to around 60°C. The agar-sucrose 
solution was then poured into a Petri dish of 5 c m diameter for solidification and was stored 
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in 40C. The solidified agar food was used within two weeks after preparation. 
2.2.4 Measurement of activity and sleep in fly 
The wide-type female CSl flies of 5-7 days old were employed in the locomotor activity 
assay. Flies were anaesthetized with CO2 on a pad made of porous material. Female flies are 
selected and a single fly was then transferred to an activity tube with a length of 65 m m and a 
diameter of 5 m m (purchased from Trikinetics) with a paintbrush. One side of the opening of 
the activity tubes were closed with a small piece of cotton wool. The agar food was prepared 
as mentioned in section 2.2.3 and was filled in a 200 |il pipette tubes to fit into another end of 
the activity tubes. The activity tubes with food and the fly were then placed on the 
Drosophila Activity Monitoring System (Trikinetics) which was housed in the 
temperature-constant incubator at 25"C for recording the data. Activity counts were recorded 
in 1-minute bins. All locomotor activity assays were conducted in the condition of 12 hour: 
12 hour light: dark cycle leaving the flies undisturbed. All experiments were replicated at 
least three times. 
2.2.5 Determining the effects of SD extract on Drosophila sleep 
The locomotor activity assay included one day for adaptation with the 1 % agar 5 % 
sucrose food. The food was then changed to agar food containing 0, 25, 50 or 100 mg/ml S D 
extract 1 hour before the onset of darkness on the second day of the experiment. The activity 
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counts on the subsequent 2 days were recorded. 
2.2.5.1 Data analysis 
Microsoft excel was used for data manipulation. Parameters of nighttime activity, 
amount of nighttime sleep and number of sleep bouts were calculated. Nighttime activity was 
calculated by summing up all the activity counts recorded in the 12 hour dark period. Sleep 
was defined as any period of uninterrupted behavioral immobility (0 counts per minute) 
lasting for greater than 5 minutes on the basis of previous work (Shaw et al., 2000;Huber et 
al., 2004). Nighttime sleep was calculated by summing up the sleep time in the dark period. 
Number of sleep bouts was calculated by counting the number of sleep episodes in the dark 
period. The result was analyzed by one-way A N O V A . 
2.2.6 Test of amount of food intake for different dosages of SD using food dye 
Female CSl flies were separated into five groups with 50 flies in each. One group of the 
flies was fed with 1 % agar 5 % sucrose without food dye and S D for blank control. The other 
groups were fed with 1 % agar 5 % sucrose food containing 0.5 mg/ml of the food dye F D & C 
Red No. 3 together with 0, 25, 50, 100 mg/ml SD, respectively. After 12 hours of feeding, the 
flies were anesthetized by CO2 and were transferred to microfuge tubes and the tubes were 
frozen in -SCfC refrigerator for 15 minutes. The flies were then homogenized in 200 i^l of 
distilled water by plastic pestle (Kontes). The homogenates were then centrifuged at 16000 x 
g for 10 minutes two times to remove residues. The supematants collected were then 
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centrifuged at 16000 x g for 20 minutes to further remove residues. After that, 100 i^l of the 
supernatants were collected in a 96-well plate for spectrophotometric measurement at 540 
nm. 
2.2.7 Survival test 
The Canton-S {CSl) wide-type fly line was used for the survival test to determine the 
toxicity of the S D extract on the flies. Female flies were used in the survival test in order to 
agree with the locomotor activity assay. Four hundred newly eclosed female flies were 
grouped into 2 treatment groups with 200 flies per group. One group was fed on standard 
food and another was fed on food containing 50 mg/ml SD. Each group was rearing in 10 
vials with 20 flies in each vial. The vials were kept in the IS'^C incubator with 12 hour: 12 
hour light: dark cycle. The flies were transferred to new vials containing fresh food every 5-7 
days and the number of live flies was counted every 2-4 days until all the flies were died. 
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2.3 Establishment of the Drosophila caffeine-induced insomnia model 
Caffeine is used as a stimulant to mimic the insomnia condition in the model for further 
investigation of the hypnotic effects of S D extract. In this thesis, to distinguish from the sleep 
model, the term caffeine-induced insomnia model was used to specifically refer to those 
experiments that used caffeine as a sleep-disrupting agent. 
2.3.1 Determining the effects of caffeine on the Drosophila sleep 
Food was prepared similar to the procedure described in section 2.2.3 except that 
caffeine stock solution was added instead of S D extract. Caffeine stock solution of 20 mg/ml 
was prepared by dissolving 0.2 g caffeine (Sigma) in 10 ml distilled water. Agar-sucrose food 
containing 0.25, 0.5, 1, 1.5, and 2.5 mg/ml of caffeine were prepared by adding appropriate 
amount of the 20 mg/ml caffeine stock solution to 15 ml agar-sucrose solution when it was 
cooled to about 60。。. Experiment procedure was similar to that mentioned in section 2.2.4 
and 2.2.5 except that the S D containing food was replaced with caffeine containing food. 
2.3.2 Determining the effects of SD extract on the Drosophila caffeine-induced insomnia model 
Food was prepared similar to the procedure described in section 2.2.3 except that 1 
mg/ml caffeine was mixed with the different concentrations of S D extract. Experiment 
procedure was similar to that described in section 2.2.4 and 2.2.5 except that the S D 
containing food was replaced with caffeine and S D containing food. 
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2.3.2.1 HPLC determination of caffeine intake in Drosophila 
H P L C analysis was used to investigate whether the palatability of the S D extract would 
affect the intake amount of caffeine in flies. Female flies were separated into four groups 
with 100 in each and each group was fed on food made up of 1 % agar and 5 % sucrose 
containing 50 mg/ml S D extract, 50 mg/ml S D extract and 1 mg/ml caffeine, 1 mg/ml 
caffeine and neither S D extract nor caffeine, respectively for 3 hours. They were then 
sacrificed by freezing in liquid nitrogen. The frozen flies were transferred to microfuge tube 
and were homogenized in 1 ml of distilled water by plastic pestle (Kontes). The homogenates 
were then centrifuged at 16,000 x g for 15 minutes. The supernatant was transferred to new 
microfuge tube and filtered by 0.2 jam filter (Iwaki). The filtered samples were stored at 
-20°C until use. 
The chromatographic method was performed in reference to previously described 
method (Kawahara et al., 2004). The H P L C system consisted of a CI8 reversed-phase 
column, 3.9 x 300 m m (Nova-Pak) connected with Agilent H P L C system, equipped with a 
Agilent D A D detector. The mobile phase was constituted by methanol: 0.15 M NaH^PCli 
(25:75, v/v). Methanol ( H P L C grade) was perchased from T E D I A and NaH2P04.2H20 was 
perchased from Riedel-de Haen. The solution 0.15 M NaHaPO* was prepared by dissolving 
23.4 g NaH2P04-2H20 in 1 L milli-Q water. Methanol and NaHsPO* solution were degassed 
and filtered before use. The mobile phase was delievered at a flow rate of 1.0 ml/min. The 
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injection volume of the sample was 20 The absorbance at 274 n m was detected and the 
areas under curve of peaks were used for analysis. Stock standard solution of caffeine (1 
mg/ml) was prepared in milli-Q water. Working standard solutions were prepared by diluting 
the stock solution in appropriate amount of milli-Q water in order to obtain concentration of 
25, 50, 100, 200, 400, 800 |ag/ml. All of the standards were stored at -20°C, 
2.3.2.2 Spectrophotometric measurement of caffeine, SD and caffeine-SD solutions 
Spectrophotometry was used as a rough detection method for the chemical interactions 
between caffeine and the S D extract. It is assumed that any interactions between the caffeine 
and components in S D extract would result in a different absorbance spectrum of the mixture. 
Aqueous solutions of the 1 mg/ml caffeine, 12.5 mg/ml SD, and 12.5 mg/ml S D extract with 
1 mg/ml caffeine were prepared and were placed at room temperature for 1 hour. The 
solutions were then diluted 200 fold and 1 ml of the diluted solutions were used for 
spectrophotometric measurement. The absorption spectra in the range 190-800 n m were 
obtained. 
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2.4 Expression of Cyp6a8，Djun and Dfos in drug-treated Drosophila heads 
Real-time polymerase chain reaction (Real-time P G R ) was used to investigate the effect 
of S D extract on gene expression level of Cyp6a8, Djun and Dfos in our model. The drug 
treatment for gene expression study was performed in triplicates. 
2.4.1 Drug treatment and collection of fly head samples 
Wide-type CSl female flies were used for studying the gene regulation upon drug 
feeding. Flies were separated into 12 groups with 30 flies per group. The groups were fed on 
3.5 c m X 3.5 cm blotting paper soaked with 400 )il 5 % sucrose solution, or 400 |il 5 % 
sucrose solution containing 1 mg/ml caffeine, 50 mg/ml S D extract, 1 mg/ml caffeine with 50 
mg/ml S D extract for 0, 2, and 4 hours, respectively. The feedings were started at 1 hour 
before the onset of dark period to normalize the effects on gene expression level by circadian 
factors. After the drug treatment, the flies were sacrificed and frozen by submerging the vials 
in liquid nitrogen. The frozen flies were transferred to 1.5 ml microfuge tube and the tubes 
were kept in liquid nitrogen for 20 minutes. The fly heads were separated from the bodies by 
hitting the microfuge tube on the bench vigorously for several times immediately after 
freezing. Twenty five heads were picked out from each group by clean forceps and collected 
in new tubes. The fly heads are stored at -80°C until R N A extraction. 
2.4.2 Total RNA extraction from fly heads 
Fly heads collected after the drug treatment were subjected to total R N A extraction. 
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Twenty fly heads were homogenized in 500 jil of TRIzol Reagent (Invitrogen) in a microfuge 
tube by a plastic pestle (Kontes). The homogenized samples were then vortexed for 5 seconds 
and incubated for 5 minutes at room temperature. After that, 100 |li1 chloroform was added to 
the homogenates and the mixtures were then shaken vigorously by hand for 15 seconds and 
incubated for 3 minutes at room temperature. The microfuge tubes containing the mixture 
were then centrifuged at 12,000 x g at 4°C for 15 minutes. The upper aqueous layer (around 
300 |il) which contained R N A was transferred to new microfuge tubes and 250 jil 
isopropanol was then added. The microfuge tubes were gently invented for three times to mix 
the contents and incubated at room temperature for 10 minutes. The samples were then 
centrifuged at 12,000 x ^ at 4°C for 10 minutes. The supernatants were then removed, 
allowing the R N A pellets remained in the bottom of the microfuge tube. The pellets were 
washed by vortexing with 500 |il 7 5 % ethanol. The tubes were then centrifuged at 7500 x g 
at 4。C for 5 minutes. The ethanol was then removed and the R N A pellets were allowed for 
air-dry for 5-10 minutes on a 95°C heat block. The R N A pellets were then resuspended in 
30 \i\ RNase-free water. The R N A samples were stored at -70°C until use. 
The quantity and purity of the R N A samples was determined by U V spectrophotometry. 
Two microliters of the R N A samples was diluted in 200 \i\ distilled water and the absorbance 
was then measured by Eppendorf BioPhotometer using distilled water as blank. The R N A 
concentration was determined by the absorbance at 260 n m (A260) by the formula: 
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R N A concentration (fig/jal) 二 A26O 乂 40/1000 x dilution factor 
The purity of the R N A sample was determined by the ratio between the absorbance 
values at 260nm and 280nm (A260/A280). Only the R N A samples with A260/A280 >1.5 would 
be used for gene expression analysis. R N A integrity was checked by running the R N A 
samples on 1 % (w/v) agarose gel-TAE gel. 
2.4.3 Real-time polymerase chain reaction analysis 
The P G R amplification was performed by QuantiFast S Y B R Green RT-PCR kit (Qiagen) 
according to the manufacturer's instruction. The reaction volume was 10 \i\ and the analysis 
of each sample was done in triplicates. Each 10 i^l reaction contained 5 |il 2x QuantiFast 
Green R T - P C R Master Mix, 0.1 \x\ QuaniFast R T Mix, 0.1 \i\ of each of the gene specific 
primers (100 ^iM) and 100 ng of the template R N A in 4.7 RNase-free water. The relative 
expression level was calculated in reference to the house-keeping gene RpLlL The reactions 
were performed using 7500 Fast Real-Time P G R system (Applied Biosystems) using the 
following protocol: 
Step Time Temperature 
Reverse Transcription 10 minutes 50。C 
P G R initial activation step 5 minutes 95°C 
Two-step cycling (repeat for 40 cycles) 
Denaturation 10 seconds 95°C 
Combined annealing/extension 30 seconds 60^ 'C 
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Fluorescence was measured after each cycle. The primer sequences used were listed in 
Table 2.2. The specificity and identity of the products was verified by melting curve analysis 
and agarose gel electrophoresis. A single product peak should be obtained in the melting 
curve if the amplification was specific. The end products were separated on a 1 % agarose gel 
to ensure that a single product in a desired length was obtained from each pair of the primers. 
Threshold cycle (Ct) values were calculated by the S D S software package vl.3.1 
(Applied Biosystems) with the default threshold setting of 0.2 and baseline range from 3 to 
15 cycles for background signal calculation. Real-time P G R amplification efficiencies were 
determined by performing P G R on a serial dilution of a R N A reference sample. The standard 
curve (threshold cycle values for each of the dilutions against log concentration) was then 
plotted and the efficiencies were calculated by the formula: 
Efficiency = \ Q(-l/slope of the standard curve) _ | 
to ensure the both primers of the target gene and the house-keeping gene have a similar 
efficiency. The relative expression level of the target m R N A was calculated using the AACt 
method. The relative expression level of the target m R N A compared to that of RpLll 
house-keeping gene was expressed as2—(〔(�—「。(/^ ；^ "/) where Cttarget and CtRpui are the 
mean threshold cycle value of the amplification reactions in triplicate for the target gene and 
RpLll respectively. 
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Table 2.2. Primer sequences used for real-time PCR analysis. 
Primer Sequence (5' ^  3') 
RpL 11 Forward C G A T C C C T C C A T C G G T A T C T 
RpL 11 Reverse A A C C A C T T C A T G G C A T C C T C 
Cyp6a8 Forward G G C T G A G G T G G A G G A G G T 
Cyp6a8 Reverse C G A T G A C G A A G T T T G G A T G A 
Djun Forward G A T C G C G T G A A G G T A C T T A A 
Djun Reverse T T A T T G G T C T G T C G A G T T C G 
Dfos Forward C T C G A C C G G C A C C T T C A A C T 
Dfos Reverse T T A T A A G C T G A C C A G C T T G G 
For each time point, the gene expression levels were compared to the control group and 
1 mg/ml caffeine group. Statistical analyses were performed with the Student，s Mest. 
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2.5 Determining the effects of SD formula on short-sleep mutants 
2.5.1 Fly stocks 
ThQ fumin and control for fumin flies were obtained from Professor F.R. Jackson (Tufts 
University School of Medicine, Massachusetts, U.S.A.) (Kume et al., 2005). The control line 
is a white strain of similar genetic background. The minisleep {mns), Hk�and the background 
control CS were obtained from Professor G. Tononi (University of Wisconsin-Madison, 
Wisconsin, U.S.A.) (Cirelli et al., 2005;Bushey et al., 2007). The CS strain is the wild-type 
background in which the mutants were discovered. All of these mutant fly lines were 
obtained in homozygous stocks. 
2.5.2 Experimental design 
For the sleep measurement, female flies of 5-7 days old for the fumin mutant and the 
Y 
control fox fumin were used, and female flies of age 7-10 days were used for the mm, Hk 
and the background control CS. The experiments consisted of 1 day of adaptation, 1 day of 
baseline sleep measurement and the 2 days of drug treatment. 
For studying the effect of S D on the mutant flies, each time the activity of the mutant fly 
line and the control fly line was measured at the same time, with the food for half of the 
mutant fly line and the half of control fly line was changed to plain food as control and the 
food for another half was changed to food containing 50 mg/ml S D one hour before the dark 
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period on the drug treatment day. Nighttime activity, nighttime sleep and number of sleep 




3.1 Establishment of the Drosophila sleep model 
3.1.1 Baseline activity and sleep 
The data from baseline activity recording of the female wide-type CSl flies is shown in 
Figure 3.1. As shown in Figure 3.1 A , activity predominated the light period with the most 
active period in the morning and evening, where as immobility predominated the dark period, 
suggesting flies were more active in the daytime, while asleep in most of the time at dark. 
The daily sleep profile (Figure 3.IB) indicates that the flies had consolidated sleep during the 
dark period. The data of sleep time calculated using the definition of sleep as immobility of 
greater than 5 minutes showed that the sleep time of the flies for daytime and nighttime were 
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Figure 3.1 Baseline sleep of wide-type flies. Data were averaged from sixteen 3-7 days 
old CSl female flies. (A) Representative activity record of flies from a 4-day 
measurement. The top bar indicates the 12 hr: 12 hr light-dark schedule (white: light 
period; black: dark period). Each horizontal line corresponds to 1 day. Flies were more 
active in the daytime. (B) A representative daily sleep profile. The amount of sleep in each 
30-min bin is plotted against the time. Data were shown as mean 土 S.E.M.. The light-dark 




3.1.2 Effect of SD on Drosophila sleep 
The hypnotic effect of S D in CSl flies was also investigated. The nighttime activity, 
sleep bout number and the total time of sleep of flies fed with different dosage of S D were 
calculated. The S D was administrated orally one hour before the dark period during the 12 
hour when sleep predominates. 
Figure 3.2A shows the nighttime activity. There was no significant difference of the 4 
treatment groups. Flies in the control group, fed with food without S D extract, passed the 
middle of the activity tube 255 ± 18 (mean 土 S.E.M.) times during the whole night. Figure 
3.2B shows the number of sleep bouts during the night. S D at the dosage of 50 mg/ml 
significantly decreased the sleep bout number (0 mg/ml S D = 11.0 土 1.0 versus 50 mg/ml 
S D = 7.1 ± 0.8 , < 0.05). Figure 3.2C shows the nighttime sleep. Only the group with the 
dosage of 50 mg/ml showed a significant increase in the total nighttime sleep (0 mg/ml = 
534.2 土 13.7 minutes versus 50 mg/ml S D 二 589.9 土 10.1 minutes, P < 0.05). In summary, 
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Figure 3.2 Effects of S D on Drosophila sleep. (A) Nighttime activity, (B) sleep 
bouts number and (C) amount of nighttime sleep of flies fed with food with 0, 25, 
50, 100 mg/ml S D respectively. Food was changed to plain food (control) or 
SD-containing food one hour before the dark period. The number of crossings per 
minute in the dark period was recorded and used for analysis. Any period with 
greater than 5 min of no crossings was counted as sleep. Results were shown as 
mean 土 S.E.IVL < 0.05. One-way A N O V A followed by Dunn's multiple 
comparison tests (n > 58 per dose). 
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3.1.3 Amount of food intake for different dosages of SD 
Food dye was used to quantify the amount of food intake by the flies as described in 
section 2.2.6 to check whether different dosages of S D would affect the intake amount. A 
slight decrease in the mean values of absorbance of fly tissue extract from the groups fed 
with S D comparing with the group without S D indicates S D may have little effect on 
preventing the flies from taking in the food. However, there was no significant difference 
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Figure 3.3 Amount of food intake for different dosages of SD. Flies were fed with 
food containing 0.5 mg/ml of food dye together with different dosages of S D for 12 
hours. The amount of S D intake was reflected by the absorbance of the dye of the 
flies tissue extracts. N o significant difference by one-way A N O V A followed by 
Dunn's test. (n=3). 
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3.1.4 Effect of SD on the survival of wide-type (CSl) flies 
The toxicity of the S D on the wide-type CSl flies was investigated with the most 
effective dosage (50 mg/ml) obtained in the activity and sleep assay (Section 3.1.2). S D 
feeding resulted a chronic deleterious effect to the adult female lifespan as shown in Figure 
3.4 ( P < 0.0001 by Log-rank test). 
In the first 25 days of the treatment, there was no much difference in the survival rates 
between the two groups. The difference in percent survival became apparent after 25 days, 
the flies in SD-treated group died in a higher rate. All the SD-treated flies died on day 61, 
while all the flies in control group died on day 77. Fifty percent of the flies in the control 
group and 50 mg/ml S D treated group died on day 58 and 37 respectively. Median survival of 
the control group and the 50 mg/ml S D treated group were 58.5 days and 41 days 
respectively. And the average lifespan of the control group and the 50 mg/ml S D treated 
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Figure 3.4 Survival test of wild type flies {CSl) by feeding SD. (A) Survival curves 
and (B) lifespan data of the flies. Newly eclosed adult female flies were fed on diets 
with 0 mg/ml (Control) and 50 mg/ml of S D respectively at 25°C. The flies were 
transferred to new vials containing fresh food every 5-7 days and the number of live 
flies was counted every 2-4 days. The initial population in each group was 200 flies. 
The m a x i m u m lifespan, 5 0 % survival time, median survival and average lifespan 
were calculated. Data were analyzed by Log-rank test. 
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3.2 Establishment of the caffeine-induced insomnia model in Drosophila 
3.2.1 Effect of Caffeine on Drosophila sleep 
As part of the establishment of the insomnia model, the effects of caffeine on the 
Drosophila sleep was also tested with different dosages of caffeine chosen in reference to the 
previous experiment (Shaw et al., 2000). The nighttime activity, sleep bout number and the 
total time of sleep were calculated from the activity data recorded on the following day by 
the Drosophila Activity Monitoring System. 
Caffeine was shown to significantly increase nighttime activity, sleep bout number, and 
decrease total nighttime sleep in a dose-dependent manner. As shown in Figure 3.5, feeding 
with 0.5 mg/ml caffeine significantly (P < 0.05) increased nighttime activity and number of 
sleep bouts, and decreased the amount of nighttime sleep. The effects of caffeine on activity, 
number of sleep bouts and nighttime sleep at the dosage 1.5 and 2.5 mg/ml were highly 
significant {P < 0.001). The nighttime activity for control, 0.5 and 2.5 mg/ml caffeine-treated 
group were 249 ± 18 (mean 土 S.E.M.), 375 土 35 and 448 士 26 respectively. The number 
of sleep bouts for control, 0.5 mg/ml and 2.5 mg/ml caffeine treated group were 12.0 土 0.9, 
16.9 土 1,0 and 22.7 土 1.2 respectively. And the nighttime sleep for control, 0.5 and 2.5 
mg/ml caffeine treated group were 557.2 土 12.6 minutes, 479.4 土 21.4 minutes and 455.1 
±15.0 minutes respectively. Caffeine decreased the amount of nighttime sleep and increased 
the number of sleep bouts, suggesting that caffeine made the sleep more fragmented, which is 
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a condition similar to the insomnia. 
The dosage of 1 mg/ml caffeine was chosen for the insomnia model because it is not a 
very high concentration, therefore having a minimal toxic effect, and its effects were quite 
significant in the three measured activity and sleep parameters. Its effect was significant (P < 
0.05) on the nighttime sleep, was very significant {P < 0.01) on nighttime activity and was 
extremely significant {P < 0.001) on number of sleep bouts. The value of nighttime activity, 
number of sleep bouts and nighttime sleep were 389 土 31, 19.4 土 1.2 and 492.6 土 15.2 
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Figure 3.5 Effect of caffeine on Drosophila sleep. (A) Nighttime activity, (B) sleep 
bouts number and (C) amount of nighttime sleep of flies fed with food with 0, 0.25, 
0.5, 1, 1.5 and 2.5 mg/ml caffeine. Food was changed to plain food (control) or 
caffeine-containing food one hour before the dark period. The number of crossings 
per minute in the dark period was recorded and used for analysis. Any period with 
greater than 5 min of no crossings was counted as sleep. Data were shown as mean 
土 S.E.M. (n > 46 per dose). *尸 <0.05, *〒<0.01, ***/>< 0.001. One-way A N O V A 
followed by Dunn's multiple comparison tests. 
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3.2.2 Effect of the SD on the caffeine-induced wakefulness 
The dosage of 1 mg/ml caffeine was used to mimic the insomnia condition as mentioned 
in section 3.2.1, that caffeine can significantly increase nighttime activity, number of bouts, 
and decrease the amount of nighttime sleep. It was of interest to know whether the S D can 
reverse the caffeine-induced insomnia condition in Drosophila. The effect of S D on the 
caffeine-induced wakefulness was investigated by feeding food with different dosage of S D 
together with 1 mg/ml caffeine. 
The result showed that S D at the dosage of 50 mg/ml can improve the insomnia 
condition induced by caffeine. Figure 3.6A shows that S D at the dosage of 50 mg/ml reduced 
the caffeine-induced hyperactivity significantly (nighttime activity for 1 mg/ml caffeine 
treated group = 383 土 31 versus nighttime activity for the 50 mg/ml group = 219 土 19,户 < 
0.01). Figure 3.6B shows that S D of all the tested dosage (25, 50 and 100 mg/ml) 
significantly reduced the number of sleep bouts that elevated by caffeine (number of sleep 
bout for the 25 mg/ml S D with 1 mg/ml caffeine, 50 mg/ml S D with 1 mg/ml and 100 mg/ml 
S D with 1 mg/ml caffeine treatment group = 9.0 土 0.7, 8.9 土 0.8 and 11.1 土 0.8 
respectively, versus number of sleep bout for the 1 mg/ml caffeine treated group =19.1 士 
1.2, P < 0.001), suggesting that S D can consolidate the fragmented sleep induced by caffeine. 
S D at the dosage of 50 mg/ml also restored the sleep to around the normal level (Total 
nighttime sleep for the 50 mg/ml S D with 1 mg/ml caffeine treatment group 二 579.5 土 12.1 
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Figure 3.6 Effect of S D on caffeine-induced wakefulness in Drosophila. (A) 
Nighttime activity, (B) sleep bouts number and (C) amount of nighttime sleep of 
flies fed on SD. Food was changed to plain food (control) or 1 mg/ml 
caffeine-containing food without or with different concentrations of S D one hour 
before the dark period。The number of crossings per minute in the dark period was 
recorded and used for analysis. Any period with greater than 5 min of no crossings 
was counted as sleep. Results were shown as mean 土 S.E.M. (n > 44 per group). *尸 
< 0.05, < 0.01, < 0.001 comparing with caffeine-only treated group. 
One-way A N O V A followed by Dunn's multiple comparison tests. 
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3.2.3 Validation of caffeine intake by HPLC 
The amount of caffeine taken in by the flies was quantified by H P L C . A single peak 
with a retention time of 7.46 minutes was obtained from the 25 |ig/ml caffeine standard 
solution (Figure 3.7A). Standard caffeine solutions were used to construct the standard curve 
(Figure 3.7B). The peak with the same retention time was used to confirm the presence of 
caffeine in the different treatment groups. 
As shown in Figure 3.8, the peak corresponding to caffeine did not appear in the control 
group and the 50 mg/ml group, suggesting caffeine was not present in the tissue extract of 
these two groups. The presence of caffeine can be detected in the tissue extract of 1 mg/ml 
caffeine treated group and 1 mg/ml caffeine and 50 mg/ml S D cotreated group, with the area 
for the peak corresponding to caffeine were 296 土 82 and 259 土 60 respectively. 
By the assumption that the greater the amount of caffeine taken in by the flies, the 
higher the concentration of the caffeine in the fly tissue extract, the amount of intake of 
caffeine was expressed in terms of the concentration of caffeine determined by the peak area 
and is shown in Figure 3.9. There is no significant difference in the amount of caffeine intake 
between the 1 mg/ml caffeine-treated group and the 1 mg/ml caffeine and 50 mg/ml S D 
co-treated group (P = 0.400); and the concentration of caffeine extracted from these tissues 
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Figure 3.7 H P L C analysis of caffeine. (A) Representative chromatogram of caffeine 
standard solution. A volume of 20 i^l caffeine standard solution of 25 [xg/ml was 
injected for H P L C analysis as described in section 2.3.2.1. A single peak with a 
retention time of 7.46 minutes was obtained. (B) Calibration Curve of Caffeine. 
Twenty of caffeine standard solutions with concentration 25, 50, 100, 200, 400 
and 800 ^ig/ml were injected for H P L C analysis as described in section 2.3.2.1 to 
obtain the peak area.. 
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Figure 3.8 Chromatograms of tissue extracts from flies after drug treatments. 
Volumes of 20 tissue extract from 100 female flies fed with (A) standard food 
(control), (B) food containing 50 mg/ml SD, (C) food containing 1 mg/ml caffeine, 
(D) food containing both 50 mg/ml S D and 1 mg/ml caffeine, respectively, for 3 
hours were injected for H P L C analysis as described in section 2.3.2.1. The peak 
corresponding to caffeine (arrows) was not found in the control group and the 
SD-only treated group, and similar amount of caffeine were found in the both the 
caffeine-only group and caffeine-SD co-treated group. 
70 
Results 





Q 6- — p 
r x i 
leaf 1caf+50SD 
Treatment Group 
Figure 3.9 Amount of caffeine intake in flies. The intake amounts in the flies treated 
with 1 mg/ml caffeine (leaf) and 1 mg/ml caffeine with 50 mg/ml S D (lcaf+50SD)’ 
respectively, were expressed in terms of the concentration of caffeine in the fly 
tissue extract. P = 0.400 by Mann-Whitney test. Data were shown as mean 土 
standard deviation (n = 3). 
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3.2.4 Spectra of caffeine, SD and caffeine-SD solutions 
If caffeine can bind to the compounds in the S D extract, the ability of caffeine in 
mimicking the insomnia condition may be changed. Therefore, the chemical interactions 
between the caffeine and S D were also investigated by the spectrophotometry. By assuming 
any chemical interactions or binding would lead to a change in the absorbance of the 
molecules, the spectra of caffeine, S D and caffeine-SD mixed solution were obtained to 
check whether the caffeine would bind to the SD. 
As shown in Figure 3.10, the spectrum for the caffeine-SD mixture was approximately 
the summation of individual spectra of caffeine and SD, meaning that caffeine did not react 
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Figure 3.10 U V spectra of caffeine, S D and caffeine-SD solutions. Solutions of 1 
mg/ml caffeine, 12.5 mg/ml SD, and 12.5 mg/ml S D with 1 mg/ml caffeine were 
prepared and placed in room temperature for 1 hour. The solutions were then diluted 
200 fold for spectrophotometric measurement. U V absorbance in the range 190-800 
n m was measured. L o w absorbance (< 0.006) was detected above 500 nm. The range 
190-500 n m was shown. Spectra were obtained from 3 repeated experiments. 
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3.3 Effect of SD on the sleep of short-sleep mutants 
In order to learn more about the hypnotic effects of SD, short-sleep fly mutants that 
have been reported to have less amount of sleep were used to test the effect of S D extract. 
3.3.1 fumin mutant 
The effect of S D was investigated on the short sleep mnXmX fumin (fmn) which have a 
mutation in the gene coding for Drosophila dopamine transporter (Kume et al, 2005). The 
mutant d D A T gene contains an insertion of heterologous D N A (a portion of wo transposon) 
into intron 6, causing an aberrant splicing at the exon 6-intron 6 junction which results in the 
termination of d D A T protein synthesis at residue 343 (Kume et al., 2005). 
To exclude the possibility that difference in sleep time maybe due to the different 
genetic background, w e used a fly strain with a similar genetic background, the control fly 
{ox fumin (contol for fmn), as control. Flies were fed with food with 50 mg/ml S D or plain 
food (control) for comparison. 
Baseline sleep result showed that the homozygous fmn mutant has significantly less 
amount of sleep {P < 0.05) in both the daytime and the nighttime (Figure 3.11). The 
nighttime activity and the numbers of sleep bouts of the fmn mutant were significantly higher 
than that of the control forfmn {P < 0.001) as shown in Figure 3.12. Nighttime activity of the 
fmn mutant and control iox fmn were 399 土 35 (mean 士 S.E.M.) and 195 ± 20 respectively 
and sleep bout number for fmn mutant and control fox fmn were 16.6 土 1.1 and 8.8 士 1.0 
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respectively. The nighttime sleep of the fmn mutant was 431.0 士 23.5 minutes, which was 
significantly less than that of control for fmn (P < 0.001) which was 584.3 ±13.6 minutes. 
The effect of S D on the wide-type control flies for fmn was also noted. Wide-type 
control flies fed with 50 mg/ml S D had a significant higher activity {P < 0.05) but less 
nighttime sleep (F < 0.05) than the wide-type control flies fed with plain food. 
For the fmn mutant, S D had no significant effects on the amount of nighttime sleep and 
the nighttime activity of the/麵 mutant comparing to the group fed with plain food. However, 
S D decreased the number of sleep bouts significantly (P <0.01) compared with the group fed 
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Figure 3.11 Daily sleep profile of fumin mutant and control foY fimin. The below 
bar indicates the light dark schedule (white: light period, black: dark period). Data 
were shown as mean 土 S.E.M. (n = 48). Black triangle on top indicates the sleep of 
the two groups at the time point is significantly different (P < 0.05, unpaired t test), 




Nighttime Activity Numbers of Sleep Bouts 
coo「 1^=0-590 I … P =0.008 
500「 I I 20「 0,001 I 1 
450 P < _ 丁 18 I 
400 m n B 16 
I - I r ^ • i r ^ I _ 
no SD SD no SD SD no SD SD no SD SD 






I 6。0 r P =0.935 
I 500 - • 幽 ‘ ‘ 
I I I • _ _ 
云 300 _ • _ _ I M 
i ：：：足 1 1 1 
no SD SD no SD SD 
wide-type fmn 
Figure 3.12 Effect of S D on fumin mutant and the control for fumin. fumin mutant 
flies (fmn) and control flies for fumin (wide-type) were fed with S D or plain food (no 
SD) one hour before the dark period (n > 56 per group). The nighttime activity (A), 
number of sleep bouts (B) and amount of nighttime sleep (C) were calculated from 
the recorded data. The P values shown were obtained by unpaired t test. 
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3.3.2 Minisleep mutant 
The effect of S D was also investigated on the short sleep mutant miniskep, which have 
a point mutation (C to T) in exon 9 of the Shaker (Sh) gene, encoding for the a subunit of a 
tetrameric potassium channel (Cirelli et al., 2005). The mutation results in a threonine to 
isoleucine substitution at the extracellular end of the transmembrane segment SI, a part of 
the voltage-sensor module of the potassium channel (Cirelli et aL, 2005). To exclude the 
possibility that difference in sleep time maybe due to the different genetic background, the 
C S with a similar genetic background was used as control. Flies were fed with food with 50 
mg/ml S D or plain food (control) for comparison. 
Baseline sleep measure showed that the miniskep mutant had significant less sleep than 
the control C S strain in most of time during the whole day (Figure 3.13). The nighttime 
activity and the numbers of sleep bouts of the miniskep mutant were significantly higher 
than that of the control C S (P < 0.001) as shown in Figure 3.14. Nighttime activity of the 
miniskep mutant and control C S were 564 土 38 (mean 土 S.E.M.) and 221 士 20 
respectively and sleep bout number for miniskep mutant and control C S were 16.9 土 1.0 
and 11.4 土 0.8 respectively. The nighttime sleep of the minisleep mutant was 465.6 土 17.1 
minutes, which was significantly less than that of control C S {P < 0.001) which was 597.5 土 
12.0 minutes. 
For the effect of S D on the control CS, similar to the result of S D on the wide-type fly in 
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section 3.1.2, 50 mg/ml S D was shown to significantly decrease the number of sleep bouts {P 
< 0.001) and significantly increase the amount of nighttime sleep (P < 0.01). Also, S D 
decreased the nighttime activity {P < 0.01) in the control C S strain. 
For the minisleep mutant, S D had no significant effects on the amount of nighttime sleep 
and the nighttime activity. A decrease in mean value of sleep bouts number by the S D was 
shown. However, the effect was insignificant {P = 0.051). 
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Figure 3.13 Daily sleep profile of minisleep mutant and C S control. The below bar 
indicates the light dark schedule (white: light period, black: dark period). Data were 
shown as mean 土 S.E.M. (n = 48). Black triangle on top indicates the sleep of the 
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Figure 3.14 Effect of S D on minisleep mutant and the C S control, minisleep mutant 
flies (mns) and background control C S flies (wide-type) were fed with S D or plain 
food (no SD) one hour before the dark period (n > 48). The nighttime activity (A), 
number of sleep bouts (B) and amount of nighttime sleep (C) were calculated from 




The effect of S D was also investigated on the short sleep mutant Hk、, which have a 
severe loss-of—function mutation in the Hyperkinetic (Hk) gene, which encodes for the P 
modulatory subunit of a tetrameric potassium channel (Bushey et al., 2007). The molecular 
lesion in the Hk mutant has not been identified yet. To exclude the possibility that difference 
in sleep time maybe due to the different genetic background, the C S with a similar genetic 
background was used as control. Flies were fed with food with 50 mg/ml S D or plain food 
(control) for comparison. 
Baseline sleep measure showed that the Hk、mutant had significant less sleep than the 
control C S strain in most of time during the night but had significant more sleep in most of 
time during daytime (Figure 3.13). The nighttime activity and the numbers of sleep bouts of 
the 描 Y mutant were significantly higher than that of the control CS {P < 0.001) as shown in 
Figure 3.16. Nighttime activity of the Hk、mutant and control CS were 253 土 37 (mean 土 
S.E.M) and 221 ±20 respectively and sleep bout number for Hk�mutant and control CS 
were 20.3 ± LI and 11.4 ± 0.8 respectively. The nighttime sleep of the Hk、mutant was 
504.8 ±16.1 minutes, which was significantly less than that of control CS (P < 0.001) 
which was 597.5 土 12.0 minutes. 
For the Hk^ mutant, S D increased the amount of nighttime sleep significantly {P < 0.001) 
to around the background control CS level and the decreased the nighttime activity (P <0.01) 
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and sleep bouts number (P < 0.05), suggesting that S D maybe able to reverse the short sleep 
condition in the Hk^ mutant. The nighttime activity of Hk、mutant fed with S D and with 
plain food were 253 土 37 and 395 土 35 respectively. The nighttime sleep of Hk、mutant fed 
with S D and with plain food were 590.6 士 17.5 and 504.8 土 16.1 respectively. The numbers 
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Figure 3.15 Daily sleep profile of Hk、mutant and C S control. The below bar 
indicates the light dark schedule (white: light period, black: dark period). Data were 
shown as mean 土 S.E.M. (n = 48), Black triangle on top indicates the sleep of the 
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Figure 3.16 Effect of S D on Hk、mutant and the C S control. Hk、mutant flies and 
background control C S flies (wide-type) were fed with S D or plain food (no SD) one 
hour before the dark period (n > 49 per group). The nighttime activity, number of 
sleep bouts and amount of nighttime sleep were calculated from the recorded data. P 
values shown were obtained by unpaired t test. 
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3.4 Effect of the SD and caffeine on gene expression 
It would be interested to investigate the molecular basis of the hypnotic effect of the S D 
extract and its effect on the caffeine-induced insomnia. The gene expression levels of a 
cytochrome P450 gene Cyp6a8, and two genes coded for activator protein-1 (AP-1) proteins 
Djun and Dfos were tested. The m R N A expression level of Cyp6a8 was tested because 
caffeine has previously been reported to induce the expression of the cytochrome P450 gene 
Cyp6a8 in Drosophila (Bhaskara et al., 2006), whose promoter region was found to contain 
multiple AP-1 regulatory sequences (Bhaskara et al., 2006). Also, expression of AP-1 
proteins have been shown to be related to caffeine-induced wakefulness in mammals 
(Basheer et al, 1999), therefore the expression levels of Djun and Dfos were also tested. 
3.4.1 Effect of the SD and caffeine on Cyp6a8 mRNA expression 
To identify the best conditions under which to measure the gene induction, expression 
levels of different exposure time course to caffeine and S D were tested. The expression levels 
at 0, 2, and 4 hours were measured. A n expression level at time 0 hour was also included to 
ensure that the original gene expression levels of Cyp6a8 in different groups were more or 
less the same before the drug treatment. Although there was some variation in the mean 
values of the gene expression levels at 0 hour, the difference among all the treatment groups 
at this time point were not significant. 
For a 2-hour exposure to caffeine and SD, the difference between the m R N A expression 
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levels of Cyp6a8 of all the treatment groups was still not significant. A 4-hour exposure to 1 
mg/ml caffeine increased the m R N A expression level significantly {P < 0.05) to about 7 folds 
(7.0 土 2.9, mean 土 standard deviation) of the control group. Increased Cyp6a8 m R N A 
expression also found in the treatment groups 1 mg/ml caffeine with 25 mg/ml SD, 1 mg/ml 
caffeine with 50 mg/ml S D and 1 mg/ml caffeine with 100 mg/ml SD, but the increase was 
much less than that in the 1 mg/ml caffeine with 100 mg/ml S D treatment group. The number 
of fold change of Cyp6a8 m R N A expression for the treatment groups 1 mg/ml caffeine with 
25 mg/ml SD, 1 mg/ml caffeine with 50 mg/ml S D and 1 mg/ml caffeine with 100 mg/ml S D 
were 10.4 土 4.1, 10.5 士 5.0, 4.9 土 3.1 respectively. Although a decrease in mean value of 
the elevated gene expression level of Cyp6a8 by 1 mg/ml caffeine was observed in the 100 
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Figure 3.17 Effect of caffeine and S D extract on m R N A expression level of Cyp6a8. 
Real-time P G R was used to quantify the Cyp6a8 m R N A level in the heads of flies 
fed with 5 % sucrose solution only (control), 5 % sucrose solution containing 50 
mg/ml S D (50SD), 5 % sucrose solution containing 1 mg/ml caffeine (leaf), 5 % 
sucrose solution containing both 25 mg/ml S D and 1 mg/ml caffeine (25SD+lcaf), 
5 % sucrose solution containing both 50 mg/ml S D and 1 mg/ml caffeine 
(50SD+lcaf) and 5 % sucrose solution containing both 100 mg/ml S D and 1 mg/ml 
caffeine (lOOSD+lcaf), respectively, for 0 (A), 2 (B), and 4 (C) hours respectively. 
All values are relative to RpLll. < 0.05 by unpaired t test comparing with 
control. Results were shown as mean 土 standard deviation (n = 3). 
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3.4.2 Effect of the SD and caffeine on Djun mRNA expression 
The effect of S D and caffeine on the gene expression level of Djun, a gene coding for an 
AP-1 proteins, was also investigated. A n expression level at time 0 hour was also included to 
ensure that the original gene expression levels of Djun in different groups were more or less 
the same before the drug treatment. The changes of gene expression level for the 0, 2, and 4 
hours of exposure to the caffeine and S D were not significant between all the treatment 
groups, suggesting that the effect of S D was not related to the regulatory mechanism of the 
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Figure 3.18 Effect of caffeine and S D extract on m R N A expression level of Djun 
Real-time P G R was used to quantify the Djun m R N A level in the heads of flies fed 
with 5 % sucrose solution only (control), 5 % sucrose solution containing 50 mg/ml 
S D (50SD), 5 % sucrose solution containing 1 mg/ml caffeine (leaf), 5 % sucrose 
solution containing both 25 mg/ml S D and 1 mg/ml caffeine (25SD+lcaf), 5 % 
sucrose solution containing both 50 mg/ml S D and 1 mg/ml caffeine (50SD+lcaf) 
and 5 % sucrose solution containing both 100 mg/ml S D and 1 mg/ml caffeine 
(lOOSD+lcaf), respectively, for 0 (A), 2 (B), and 4 (C) hours respectively. All values 
are relative to RpLlL Results were shown as mean 土 standard deviation (n 二 3). 
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3.4.3 Effect of the SD and caffeine on Dfos mRNA expression 
The effect of S D and caffeine on the gene expression level of another gene coding for an 
AP-1 proteins Dfos was also investigated after a 4 hour-exposure. The changes of Dfos 
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Figure 3.19 Effect of caffeine and S D extract on m R N A expression level of Dfos. 
Real-time P G R was used to quantify the Dfos m R N A level in the heads of flies fed 
with 5 % sucrose solution only (control), 5 % sucrose solution containing 50 mg/ml 
S D (50SD), 5 % sucrose solution containing 1 mg/ml caffeine (leaf), and 5 % sucrose 
solution containing both 50 mg/ml S D and 1 mg/ml caffeine (50SD+lcaf), 
respectively, for 4 hours. All values are relative to RpLlL Results were shown as 




Current treatment for insomnia relies to a great extent on the use of hypnotics. However, 
many of the available drugs, though effective, are limited at short term usage, and a variety of 
undesirable effects will be developed on continuous use of the hypnotic drugs. For example, 
the widely used benzodiazepine receptor agonists often associated with adverse effects like 
residual daytime sedation, memory and cognitive impairment, psychological and physical 
dependence, tolerance, and motor dysfunction. Newer generation of benzodiazepine receptor 
agonists, such as Zolpidem and Zaleplon, are more selective and have fewer side effects than 
the older ones, but their problem of residual side effects is still a major concern in clinics. 
Therefore, the need for developing novel sleep-promoting agents which can be used in long 
term and with milder adverse effect is desirable. Chinese herbal medicine was renowned for 
its milder side effect and potential effectiveness for long term treatment of insomnia. 
However, the scientific evidence and understanding of molecular basis for using Chinese 
herbal formula was insufficient. Therefore, the hypnotic effect of a Chinese herbal medicine 
formula SD, which was developed based on multiple folk formula, is worth evaluated. 
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4.1 Rationales for evaluating the effect of SD formula in Drosophila model 
Animal models are useful tools for evaluating the efficacy of drug in pre-clinical test. 
The use of animal models screens out drugs that without satisfactory efficacy, preventing 
them from going into clinical study and thus can save lots of resources and time on the whole 
process of drug development. O n the other hand, animal models can also provide valuable 
information on the regulatory mechanism and functions of poorly understood biological 
processes. 
Drosophila is a good choice for studying sleep. It has been a good model in studying 
genetics and development. The discovery of sleep-like behavior in Drosophila has led to a 
rigorous research on sleep using Drosophila as model. For its advantage that Drosophila is 
small that requires little space for culturing, but yet complex enough to model sophisticated 
human behaviors. It has most of the conserved genes coding for neurotransmitters and genes 
for development of central nervous system as revealed by the completed fly genome, 
implicating the great similarity of nervous system to human. The short life cycle allows quick 
genetic manipulations and expansion of a few mutants to a large population in a short time 
for experiment, allowing studying a large number of mutants at a low cost. With a number of 
characteristics of sleep shared between mammals and fruit flies, it is now know that 
Drosophila can be also a good model in sleep (Shaw et al., 2000;Hendricks et al., 
2000a;Shaw, 2003). Another advantage for using the ily to studying sleep in comparison to 
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using rat is that flies sleep in night same as human, when rats are nocturnal animals whose 




4.2 Establishment of the Drosophila Sleep model 
Use of flies - sex, gender and number 
Female flies were used because they are reported to have less nap in the daytime (Koh et 
al., 2006;Huber et al., 2004). Male flies show a narrower distribution of activity around 
morning and evening and a more pronounced nap in the middle of the daytime 
(Helfrich-Forster, 2000). The more continuous activity during daytime allows the sleep 
pattern in the female flies much easier to be observed in the activity record. 
Young flies are preferred to be used in the experiments because they have lower 
probabilities to die during the course of the experiment. Moreover, older flies are less 
rhythmic in activity. Therefore using younger flies can reduce variation between experiments. 
W e used fly in the age range 5-7 day old fly in reference to experiments done by other 
researchers (Huber et al., 2004;Shaw et al, 2000). 
According to literature, the minimum number of flies for a given genotype that need to 
be tested in order to get to a reliable estimate of sleep parameters is usually 16 and repeated 
measurements of across several generations are preferred as sleep parameters in some 
genotypes can show variability over time in apparently similar conditions (Andretic and 





The sleep in wide-type flies was evaluated in the model. Similar to the observation 
reported by previous experiments, flies were found to be more active in daytime and their 
sleep predominates during the night. The amount of nighttime sleep obtained in the model 
was similar to the magnitudes of wide-type flies reported by the other group: nighttime sleep 
reported by Ruber et al. was 594 土 6.7 (mean 土 S.E.M) minutes (Ruber et al, 2004) and 
that reported by Andretic and Shaw (2005) was 571.4 土 3.4 minutes comparing with the 
nighttime sleep measured in the model was 597.5 土 30.0 minutes. The number of sleep bout 
number was also near to that reported by other: Andretic and Shaw (2005) reported 10.4 土 
0.2 and that measured in the model was 11.0 土 1.0. However, the daytime sleep measured in 
our female flies was higher than that reported by other groups: Ruber et al. (2004) reported 
152.0 土 7.4 minutes and that reported by Andretic and Shaw (2005) was 147.5 土 4.2 
minutes, comparing to ours which was only 314.1 土 46.9 minutes. These m a y due to 
different genetic background or slight difference in the culture environment. With the similar 
range of sleep and sleep bout number obtained, I conclude that the Drosophila sleep model 
was successfully established. 
4.2.1 Hypnotic effect of SD in Drosophila 
The hypnotic effect of S D was next investigated. Based on the observation of the effect 
of S D on the Drosophila sleep, it is concluded that S D can increase the duration of sleep and 
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consolidate sleep. In the study investigating the different dosages of S D on the Drosophila 
model, S D at 50 mg/ml can reduce the number of sleep bouts and increase the amount of 
nighttime sleep (Figure 3.2). The results of these two parameters together suggested that the 
duration of every sleep episode in the night was increased by the S D extract. In other words, 
the sleep was more consolidated after the administration of S D extract. 
Different dosages of S D were administrated through supplying the food mixed with 
different amount of S D as in most of the Drosophila drug feeding experiment conducted. 
Therefore all the dosages shown in our study was expressed as the concentrations of drug in 
the food. The optimal dosage for oral administration of S D in the Drosophila model was 50 
mg/ml. W h e n both a higher (100 mg/ml) and a lower dosage (50 mg/ml) tested showed an 
insignificant effect in both reducing the sleep bout number and inducing sleep (Figure 3.2). 
The amounts of food intake for different dosages of S D were also quantified using food 
dye. The results suggested S D at different dosages did not significantly change the amount of 
food intake by the flies (Figure 3.3). Therefore, the higher dosage groups should have taken 
in grater amount of S D than the lower dosages groups, which means that there was a possible 
biphasic effect for the S D extract on the sleep. 
4.2.2 Toxicity of SD extract in fly 
In reality, the efficacy of a therapeutic agent is as important as the issues of safety. To 
address the problem of drug toxicity, the survival test of wide-type flies feeding on food 
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containing 50 mg/ml S D , which was the most effective dosage in inducing sleep, was 
performed. The results indicate S D exerted chronic toxicity to the flies. S D exhibited 
deleterious effect on the survival of fly by significantly reducing the rate of survival after day 
25 (Figure 3.4). However, it should be noted the difference of the set up of this experiment to 
the real situation of drug administration in human. In the experiment, flies were fed with S D 
containing food in a continuous mode. In contrast to that in real situation in human, they 
would not continuously take in hypnotics in the diets for treatment. Separate doses of 
administration of drug before sleep would be used in the c o m m o n way. Furthermore, the 
effect of the toxicity became only apparent after day 25, which was a long period of time 
after the starting day of the drug treatment, comparing with the period for drug treatment in 
the experiment which was only two days, while the effect of S D can be observed 
immediately on the night of drug feeding. This implies that the S D should be safe to use in 
vivo. However, it should also be noted that S D when used in long-term shortened the lifespan 
in flies. This detrimental effect has to be worried when using S D for treatment in human. 
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4.3 Effect of SD on Drosophila caffeine-induced insomnia model 
The results demonstrate the use of caffeine to mimic the insomnia condition in 
Drosophila for modeling insomnia (Figure 3.6) and also the utility of this insomnia model to 
evaluate of the effect of the Chinese herbal formula SD. 
It is difficult to have a single standard animal model for the evaluating insomnia, since 
the causes of insomnia are various and the causes are often occur together in combination to 
worsen and perpetuate the insomnia condition. Using a single model to represent all the 
different conditions of insomnia is not possible. Several models of sleep disturbance using 
different methods to disrupt sleep have been reported for evaluating the effect of hypnotics in 
literature, for example, methods using mechanical and environmental stimulating such as 
placing rats on a grid suspended over water (Shinomiya et al., 2004), stimulating rats using 
noise disturbance (Cluydts et al., 1995;Rabat et al., 2005), and mechanistic deprivation of the 
animals from sleep (Guzman-Marin et al., 2006) has been described. Other methods using 
chemicals such as caffeine (Paterson et al” 2007) and 5-HT antagonist (Leon-Ponte et al., 
2007) to disrupt sleep has also been reported. Some of these models were not intended to 
design for mimicking the condition of insomnia but for studying different regulatory 
mechanism of sleep. The difference of sleep deprivation between insomnia should also be 
noted that insomnia is a condition that one cannot sleep despite plenty of opportunities for 
sleep, but not compulsory wakefulness. Chemical-induced insomnia appears to be a more 
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representative model to the clinical situation which allows direct comparison between an 
animal model and a clinical situation. So that compounds can be assessed early in drug 
development and outcome in humans predicted. 
Caffeine was chosen as the sleep disrupting agent in our Drosophila insomnia model 
because caffeine has been reported to decrease the amount of nighttime sleep in a 
dose-dependent manner (Shaw et al., 2000) indicating a possible pre-clinical model of 
insomnia and that it has also been used in the insomnia model in rats (Paterson et al., 2007). 
In mammals, caffeine is an adenosine receptor blocker. It blocks the binding of 
adenosine, which is a well-studied sleep promoting agent, to the adenosine receptor, 
therefore inducing alertness (Fisone et al” 2004). The detrimental effects of caffeine on sleep 
quality in humans are also well documented, and clinical model of insomnia using caffeine to 
disrupt sleep has previously been described in healthy volunteers (Bonnet and Arand，1992). 
In another study, volunteers also reported a decrease in subjective sleep quality (Hindmarch 
et al., 2000). Caffeine at bedtime prolonged sleep onset latency and increased wakefulness, 
resulting in an overall decrease in total sleep time and efficiency, which is more similar to the 
real insomnia condition. 
The finding indicated that S D at the dosage of 50 mg/ml can attenuate caffeine-induced 
insomnia in the Drosophila model. Increased amount of sleep and decrease number of sleep 
episodes suggested that S D consolidates the nighttime sleep in the insomnia model. This 
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further supports the use of S D formula for treating insomnia. 
4.3.1 Drug administration in Drosophila 
In the present study, the amount of caffeine administrated in the flies was evaluated. For 
pharmacological study in Drosophila, though different drug administration methods have 
been described and used, such as drug volatilization and drug application methods (Manev et 
al., 2003), a typical way of administrating drugs to fruit flies is achieved by mixing the drugs 
in the food. The method of drug feeding for drug administration relies on the feeding on the 
food up to the free will of the flies. Therefore, it is difficult to control the amount of drug 
administered and the dosage of drug in each individual flies can vary. It is also possible that 
the flies do not ingest food to which chemicals have been added (Manev et al., 2003). A 
better method to control the dose of pharmacological agents administrated can be achieved 
via injection (Manev et al., 2003). However, microinjection method is technically 
challenging and time-consuming, which requires laborious and experienced operations. 
To address this issue and to validate the caffeine-induced insomnia model, it is 
important to ensure that the S D did not change the amount of food taken in by the flies, so 
that to ensure that the amount of caffeine taken in by the caffeine treated groups and 
caffeine-SD groups are at similar level. Answering questions such as whether the fly have 
taken in the food and whether the presence of drug would alter the amount of food taken are 
important issues in order to make reasonable conclusion from this insomnia model. 
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If reduced amount of food is taken by the Hies by the SD, a less amount of caffeine 
would be taken, meaning that the stimulating effect is lowered by the decrease in the actual 
intake amount of the food (and thus caffeine) but not by the hypnotic effect of S D , because 
the effect on activity of caffeine should theoretically depend on the concentration of caffeine. 
Therefore, it would be important to quantify the amount of intake of caffeine by the fly. 
Another reason for that w e measure the concentration of caffeine but not S D is that because it 
is difficult to find a marker for S D in H P L C . 
Determining amount of drugs intake by the fly in general is a challenging task. Method 
using food dye has been used to quantify the amount of intake of food into the fruit flies. 
However, it is not quantitative enough in measuring the intake amount of a certain drug. 
Hence H P L C method is used to validate our model. H P L C methods have been used in 
measuring the endogenous hormones in insects and chemicals in plasma samples from 
human. It would be a good method in quantify the amount of certain chemical present in the 
fruit fly. 
In the model, it has been shown that the intake amount of caffeine measured was more 
or less the same between the two groups. This suggests that the increase in sleep time should 
not be due to the reduced intake of caffeine by the S D but by the hypnotic effect per se. 
Another problem is that caffeine would possibly chemically interact with or be chelated 
by the compounds in the S D extract when they are mixed together in the food. This may 
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affect the uptake of caffeine to the site of action and may affect the sleep disrupting action of 
caffeine as it may not be recognized by the specific receptor if it was bound to other 
molecules. To investigate whether the caffeine would chemically interact with compounds in 
SD, spectrophotometric method was employed to study their interaction. By the assumption 
that change in absorbance would occur if there was chemical reaction or binding between the 
caffeine and compounds in SD, the result demonstrated that the caffeine should not interact 




4.4 Effect of SD on Short-sleep mutant 
The effect of S D extract on different short-sleep mutants was also tested. Whether S D 
can improve the short-sleep condition in a certain mutation may provide us some information 
on the working mechanism of S D and also different mutants can serve as insomnia models 
for different conditions. 
First, the baseline sleep and activity of these mutants were tested to confirm they are 
really 'short-sleep'. Our baseline recording of all the mutants, have shown a significant 
decrease in the nighttime sleep, similar to that previous reported, and increase in sleep bout 
number and nighttime activity compared with the corresponding background control fly lines, 
suggesting they can be used in our model to be alternative models of insomnia. 
One of the tested mutants fumin has a mutation in the Drosophila homolog of the 
mammalian dopamine transporter (dDAT) (Kume et al., 2005). The fumin mutant has an 
increased the dopamine signaling, presumably due to an elevated persistence of release 
dopamine caused by the loss of the dopamine transporter, therefore the mutant has less sleep. 
In mouse, loss of this gene also leads to hyperactivity (Giros et al., 1996). Hence I 
investigated the effect of S D on this model to see whether S D can reverse those increased 
dopamine signaling. The S D feeding experiment showed no significant effect on the 
nighttime activity and sleep of the./画>? mutant fly, suggesting S D did not be able to reverse 
the increased dopaminergic signaling in the mutant. However, a significant decrease in the 
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number of sleep bouts by S D was observed. The decrease in sleep bouts m a y reflect some 
sleep consolidating effect of S D , which m a y possibly act through other pathways. 
The second mutant fly line used to investigate the effect of S D was the minisleep mutant. 
It carries a mutation on the Shaker gene, which encodes for the a subunit of a highly 
conserved voltage-dependent potassium channel that heavily expressed in the C N S , which 
controls membrane repolarization and transmitter release (Cirelli et al., 2005). Mutation in 
the Shaker gene can cause repetitive nerve firing and prolonged transmitter release at the 
neuromuscular junction (Stem and Ganetzky, 1989). In mammals, sleep disorders related to 
abnormal potassium channel function are accompanied by hyperactivity and restlessness. 
(Stern and Ganetzky, 1989;Josephs et al., 2004). Therefore, it would be of interest to 
investigate whether the S D can rescue this condition. The result of the minisleep mutant was 
similar to that of ihe fumin mutant, S D showed no significant effect on the nighttime sleep 
and nighttime activity, which possibly means that the effect of S D should be related to the 
abnormal nerve firing caused by this mutation. The sleep bout number was also significantly 
decreased by the S D in the minisleep mutant. This, again, m a y indicate that S D can have 
some sleep-consolidating effect by some other unknown pathways. 
S D showed a significant effect on increasing the sleep in the third mutant, H k \ that 
have been investigated. The Hk�mutant carries a mutant in the Hyperkinetic {Hk) gene, 
which encodes for the p modulatory subunit of the Shaker voltage-dependent potassium 
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channel (Bushey et al., 2007), its presence increases current amplitude and alters both voltage 
dependence and kinetics of inactivation and activation (Chouinard et al., 1995). The mutation 
in the Hyperkinetic gene can modify the voltage dependence and kinetics of Shaker channel 
currents (Ueda and W u , 2008). The result showed that S D could increase sleep time, decrease 
nighttime activity and sleep bouts in the Hk、mutant. This indicates that S D may be able to 
rescue the abnormal condition caused by mutated modulatory subunit of the Shaker channel. 
However, this effect of S D requires further examinations to confirm. This perhaps can be 
done by measuring whether S D can affect the firing properties of Drosophila neurons with 
and without these mutated channels using the patch-clamp techniques. 
In summary, it is concluded that S D cannot improve the short-sleep condition in the 
fumin and minisleep mutants. This implies that S D m a y be not able to relief some insomnia 
conditions. The significant effect of S D in the mutant Hk�may suggest the working 
mechanism of S D is related to the modulating effect of a potassium channel. However, 
further studies are required to confirm this potential effect via the channel. 
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4.5 Study of gene expression by SD 
Research in animal model systems offers substantial advantages for identifying and 
studying genes involved in regulating complex behavior. In this study, it would be of interest 
to find some molecular targets which m a y be able to reflect the action of SD. 
Three genes which have been shown to be involved in the activator protein 1 (AP-1) 
regulation of genes were picked for study. AP-1 is a transcription factor mainly composed of 
Jun, Fos and A T F protein dimers. The transcription factor AP-1 plays role in cell 
proliferation and differentiation, survival and apoptosis (Hess et al., 2004). It regulates the 
transcription of a number of target genes in response to extracellular stimuli, including 
cytokines, growth factors, stress signals, bacterial and viral infections (Hess et al., 2004). The 
regulatory role of AP-1 has been shown also related to sleep in mammals. It has been shown 
that AP-1 activity is associated with changed of sleep-waking states and variable periods of 
sleep deprivation. For example, either spontaneous or enforced wakefulness produces 
selective induction of both m R N A and protein level of c-fos in brain regions that are active 
during wakefulness, while sleep generally reduces c-fos m R N A and protein throughout the 
brain except in a cluster of cells in the ventral lateral preoptic (VLPO) area, which is a 
sleep-promoting area in the brain, where c-fos is induced in response to sleep (Basheer and 
Shiromani, 2001). In mammals, the expression of c-fos has also been shown to be induced by 
caffeine (Murphy et al., 2003；Svenningsson et al., 1996;Dassesse et al., 1999). 
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B y examining the expression of AP-1 related genes, which m a y reveal the A P I activity 
in the Drosophila, it will be possible to better understand the effects of S D on this cascade. 
The gene expression level of Cyp6a8 was included because it has been reported to be 
upregulated by caffeine and also its promoter region contains multiple AP-1 binding 
sequences (Bhaskara et al., 2006), therefore its m R N A expression level may reflect the AP-1 
activity. The expression of Djun was also tested, since Djim is a component of the AP-1 
transcription factor. Though the expression of Dfos has been reported to be a 
circadian-dependent but not sleep/wake state-dependent genes (Shaw et al., 2000), whose 
expression level was higher during the dark hours, it would be interested to test whether 
caffeine can raise the expression of Dfos in Drosophila as that in mammals and whether its 
expression level would be related to the hypnotic effect of SD. 
In the experiment, the expression level on multiple time points was tested to identify the 
best condition for measuring the change in gene expression level by caffeine and SD. The 
time points 0, 2, and 4 hours were used because it has been described that peak expression of 
Dfos and Djun come at 1-2 hours after perturbation (Xia and Goldstein, 1999). Therefore a 
4-hour exposure time should be able to see a change in Dfos and Djun if their expression 
would be altered by caffeine or SD. Furthermore, similar time range for the induction of 
AP-1 genes by caffeine has been observed in rats (Svenningsson et al., 1995). 
The result showed that caffeine increased the expression of Cyp6a8 as previously 
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reported. Similar level of increased expression of Cyp6a8 also observed in the group treated 
with 25 and 50 mg/ml S D together with 1 mg/ml caffeine. If the hypnotic effect of S D 
involved the change of AP-1 activity, it should be expected there would be a difference in 
gene expression of Cyp6a8 at the dose 50 mg/ml, since it is the most effective dosage shown 
to improve the caffeine-induced insomnia in the model, but this was not the case. This 
indicates that the hypnotic effect of S D should not be related to the AP-1 pathway. One point 
to add is that in the quantification of caffeine administration test, only the concentration of 
the most effective dosage 50 mg/ml was tested, therefore, although a decreased mean 
expression level ofCyp6a8 at the dosage of 100 mg/ml S D was observed, this can be due to a 
reduced intake of caffeine by the high concentration of SD. And further experiments should 
be performed to check whether S D at this level would decrease the intake of food by the 
flies. 
For the Djun and Dfos m R N A expression level, no significant change can be observed. 
This also suggested that S D and caffeine did not alter the AP-1 activity in fly. Moreover, this 
m a y imply that caffeine cannot induce a change of the Dfos expression level in the brain of 
fly as that in mammals. However, before reaching such a conclusion it should also be noted 
that the gene expression levels shown in the experiment were detected from the total m R N A 
of the whole fly head but not specific part of brain. It is possible that Dfos induction has 
appeared in some specific area of the brain in fly, but it was masked by the gene expression 
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of other part of the fly brain. Therefore it would be interesting to know whether method such 
as in situ hybridization, which can study gene expression in specific part of the brain, can 
report the change of m R N A level of Dfos by caffeine in fly brain. However, due to time 
limitation, this kind of experiments could not be performed in the study. And, a difficulty in 
studying gene expression in specific region of the brain is that not much information on the 
neuroanatomy of fly and also that invertebrate animal may have a distinctly different 
neuroanatomy to human, making the results less representative for condition in human. 
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4.6 Limitations of the model 
Drosophila holds exciting prospects as a model organism for sleep, but as other model 
organism, it has its advantages and also limitations. One shortcoming of the Drosophila sleep 
model is that inherent variability of behavioral data makes it necessary to use a large numbers 
of individual flies to obtain statistically significant results (Ho and Sehgal，2005). This could 
be a potential serious drawback for drug screening in that a potential effective drug would be 
sieved out from the screening if its effect was decided as insignificant by a preliminary test 
that used an insufficient number of flies. 
Another limitation is that the popular method of measuring sleep using the Trikinetics 
activity monitors does not allow a direct measurement of sleep (Ho and Sehgal, 2005). The 
quantification of sleep is a measurement of the number of zero counts in a certain period of 
time. However, a period of absence of activity counts does not equal to that the fly is sleeping. 
It is possible that the fly is doing other things besides sleep. For examples, they can be 
walking at one half of the activity tube, eating, or grooming. Waking can be mis-scored as 
sleep if the flies do not pass through the mid-line when they are not sleeping. And 
documenting these behaviors using videography method for further validation of the data is 
time-consuming that it requires lots of time for data processing, and is limited by the 
computer memory and processing speed. 
For pharmacological study of sleep in fly, the pleiotropic effects of the drug should be 
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also noted (Ho and Sehgal, 2005). It is possible that for a drug that having nothing to do with 
sleep to have apparent effect of drug in the sleep model if the drug compromises the 
locomotor, coordination, or other system of the fly. The fly may appear to be sleeping more 
in response to a drug but in fact it is unable or unwilling to move. Therefore the flies must be 
examined manually to determine whether they have any abnormality in locomotion and/or 
are awake but not crossing the midline of the tube, to exclude the possibility of poor activity 
caused by sick or impaired health status of the fly. 
Another limitation of using fly for pharmacological study of sleep in fly is that most of 
the regulatory mechanisms of sleep that known in human have not been well studied in flies. 
Therefore, assumptions that Drosophila shares the same mechanism of regulation in sleep 
may not be always applicable. For example, it has been found that receptor specificities for 
drugs, based on work done in mammals, may not be the same in insects (Magazanik and 
Fedorova, 2003). It is possible that a certain drug can have different mechanisms of action in 
tlies and in humans. 
For the limitation of the insomnia model, this model as other animal model does not 
allow us to study the individual's subjective experience of difficulty in sleep, which is one of 
the crucial criteria for defining insomnia. Change in sleep time is always used instead to 
reflect the efficacy of the drug on treating insomnia. 
Moreover, in the model the drug is placed in the food, and in such an experimental set 
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up, the food is actually a part of the sleep environment of the fly. It is difficult to predict h o w 
the scene or color of the drug would affect their normal behavior. A n d all these factors in the 
model were just assumed to be same for the control and drug treatment group in the model. 
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5. Conclusion and Future Prospects 
5.1 Conclusion 
The present study demonstrates the utility of the Drosophila model for studying 
hypnotic effects of drug. It provides the first evidence that the Chinese herbal formula S D 
exerts hypnotic effect in Drosophila and shows that S D can improve the caffeine-induced 
insomnia condition in Drosophila. This implies the potential effectiveness and use of the S D 
formula for treating insomnia in humans, which further supports the use of S D for the 
treatment of insomnia in humans. 
Results from the study of the effects of S D on short sleep mutants suggest that the action 
mechanism of S D may be related to the (3 subunit of a potassium channel, which is a gene 
heavily expressed in the C N S . However, further experiments should be performed to confirm 
whether the effect of S D on regulatory mechanism of sleep via this potassium channel. 
5.2 Future prospects 
Although the insomnia model in Drosophila is successfully established, experiments are 
still needed to further validate the model. One of these experiments is to test the effect of 
some hypnotic control in the model, which can further support the use of this model on drug 
screening. 
In the experiment, test of the change of expression level of only a few genes have been 
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performed. And the effects of S D on the short-sleep mutants also need other experiment to 
further confirm. Therefore, the information obtained about the action mechanism of S D is 
limited. Genome-wide study of gene regulation perhaps can be used as a more powerful way 
to study the underlying working mechanism of the SD. Perhaps comparing expression 
profiles of different sleep mutants may reflect the mechanisms of SD. Action of mechanisms 
of S D which involved neurotransmitter receptor bindings could be also studied by measuring 
the binding affinities of compounds in S D to different neurotransmitter receptors. And 
different neurotransmitter receptor blockers with and without S D can be also used to examine 
the effect of S D on sleep. 
Also, ill this study, only the hypnotic effect of S D has been evaluated; however, the 
effectiveness of a therapeutic agent in other aspects of insomnia should be also tested for a 
more complete study on the effectiveness. For example, questions such as whether the S D 
when administration in long term would cause any adverse effects still not yet answered. It 
would also be of interest to see whether S D can improve other insomnia-related symptoms, 
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